

FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <b>A33606-PCT USA</b>	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <b>09/647965</b>			
INTERNATIONAL APPLICATION NO. <b>PCT/CA99/00314</b>	INTERNATIONAL FILING DATE <b>07 April 1999</b>	PRIORITY DATE CLAIMED <b>07 April 1998</b>			
TITLE OF INVENTION <b>HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINS</b>					
APPLICANT(S) FOR DO/EO/US <b>HISCOTT, John and LIN, Rongtuan</b>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2))             <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li>7. <input type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> <li>8. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>10. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li>12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> </ol>					
<b>Items 13 to 20 below concern document(s) or information included:</b>					
<ol style="list-style-type: none"> <li>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>17. <input type="checkbox"/> A substitute specification.</li> <li>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>19. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail</li> <li>20. <input checked="" type="checkbox"/> Other items or information:</li> </ol>					
<p><b>A postcard.</b></p> <p><b>Express Mail No. : EK839862405US</b>  <b>Date of Deposit: 6 October 2000</b></p>					

U.S. APPLICATION NO (IF KNOWN) 09/647965	INTERNATIONAL APPLICATION NO. PCT/CA99/00314	ATTORNEY'S DOCKET NUMBER A33606-PCT USA
--	--	---

21. The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO .....	\$1,000.00
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....	\$860.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....	\$710.00
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....	\$690.00
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) .....	\$100.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

**\$860.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than  20  30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	107 - 20 =	87	x \$18.00	<b>\$1,566.00</b>
Independent claims	4 - 3 =	1	x \$80.00	<b>\$80.00</b>

Multiple Dependent Claims (check if applicable).  **\$270.00**

**TOTAL OF ABOVE CALCULATIONS =** **\$2,776.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).  **\$1,388.00**

**SUBTOTAL =** **\$1,388.00**

Processing fee of **\$130.00** for furnishing the English translation later than  20  30 months from the earliest claimed priority date (37 CFR 1.492 (f)). + **\$0.00**

**TOTAL NATIONAL FEE =** **\$1,388.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).  **\$0.00**

**TOTAL FEES ENCLOSED =** **\$1,388.00**


	Amount to be: <u>refunded</u>	\$
	charged	\$

- A check in the amount of \_\_\_\_\_ to cover the above fees is enclosed.
- Please charge my Deposit Account No. **02-4377** in the amount of **\$1,388.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **02-4377** A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Rochelle K. Seide, Ph.D.  
BAKER BOTTS LLP  
30 Rockefeller Plaza  
New York, NY 10112-0228

  
SIGNATURE

**Rochelle K. Seide, Ph.D.**

NAME

**32,300**

REGISTRATION NUMBER

**6 October 2000**

DATE

09/647965  
528 Rec'd PCT/PTO 06 OCT 2000

A33606-PCT USA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : HISCOTT, John et al.  
Serial No. : To be assigned  
Filed : April 7, 1999  
For : HIGHLY ACTIVE FORMS OF INTERFERON  
REGULATORY FACTOR PROTEINS

**EXPRESS MAIL CERTIFICATION**

Express Mail Mailing No. EJ839862405US

Date of Deposit - October 6, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to: Box PCT, Assistant Commissioner for Patents, Washington, D.C., 20231.



Signature of person mailing correspondence

Name of person mailing correspondence: LOUIS LAFFITTE

09/647965

528 Rec'd PCT/PTO 06 OCT 2000

A33606-PCT USA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : HISCOTT, John et al.  
Serial No. : To be assigned  
Filed : 07 April 1999  
For : HIGHLY ACTIVE FORMS OF INTERFERON  
REGULATORY FACTOR PROTEINS

Express Mail Mailing No. **EK83996330US**

**PRELIMINARY AMENDMENT**

Assistant Commissioner of Patent  
Box PCT  
Washington, D.C., 20231

Sir or Madam:

Prior to examination of the above-identified application, please make the following amendments:

**IN THE CLAIMS:**

Please cancel Claims 28 to 31 without prejudice.

Claim 5, Line 25: please delete "to 4" and substitute therefor --or 2--.

Claim 6, Line 2: please delete "to 4" and substitute therefor --or 2--.

Claim 23, Line 8: please delete "The nucleotide sequence according to claim 22, having" and substitute therefore --A nucleotide sequence comprising--.

Claim 24, Line 11: please delete "The nucleotide sequence according to claim 22, having" and substitute therefore --A nucleotide sequence comprising--.

Claim 25, Line 14: please delete "The nucleotide sequence according to claim 22, having" and substitute therefore --A nucleotide sequence comprising--.

Claim 26, Line 19: please delete "to 21" and substitute therefor --or 2--.


Claim 34, Line 21: please delete "to 21" and substitute therefor--or 2--.

REMARKS

Favorable consideration and allowance of all pending claims is respectfully requested.

Respectfully submitted,

BAKER BOTTS LLP



Rochelle K. Seide  
Reg. No. 32,300  
Attorney for the Applicant  
Tel. (212) 705-5000

Dated: October 6, 2000

HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINSBACKGROUND OF THE INVENTION

Interferons (IFNs) are a large family of multifunctional secreted proteins involved in antiviral defence, cell growth regulation and immune activation (63). Virus infection induces the transcription and synthesis of multiple IFN genes (33, 52, 63); newly synthesized IFN interacts with neighbouring cells through cell surface receptors and the JAK-STAT signalling pathway, resulting in the induction of over 30 new cellular proteins that mediate the diverse functions of the IFNs (17, 35, 39, 58). Among the many virus- and IFN-inducible proteins are the growing family of IRF transcription factors, the Interferon Regulatory Factors (IRFs).

IRF-1 and IRF-2 are the best characterized members of this family, originally identified by studies of the transcriptional regulation of the human IFN- $\beta$  gene (22, 23, 30, 47). Their discovery preceded the recent expansion of this group of IFN-responsive proteins which now include seven other members: IRF-3, IRF-4/Pip/ICSAT, IRF-5, IRF-6, IRF-7, ISGF3 $\gamma$ /p48 and ICSBP (48). Structurally, the Myb oncoproteins share homology with the IRF family, although its relationship to the IFN system is unclear (62). Recent evidence also demonstrates the presence of virally encoded analogue of cellular IRFs - vIRF in the genome of human herpes virus 8 (HHV8) (55).

The presence of IRF-like binding sites in the promoter region of the IFNA and IFNB genes implicated the IRF factors as essential mediators of the induction of IFN genes. The original results of Harada et al. (30, 32) indicated that IFN gene induction was activated by IRF-1, while the related IRF-2 factor suppressed IFN expression. However, the essential role of IRF-1 and IRF-2 in the regulation of IFNA and IFNB gene expression has become controversial with the observation that mice containing homozygous deletion of IRF-1 or IRF-2, or fibroblasts derived from these mice, induced IFNA and IFNB gene

expression after virus infection to the same level as the wild-type mice or cells (44).

On the other hand, IRF-1 was shown to have an important role in the antiviral effects of IFNs (44,54). IRF-1 binds to the ISRE element present in many IFN-inducible gene promoters and activates expression of some of these genes (54). However, activation of ISG genes by IFNA and IFNB was shown to be mediated generally by the multiprotein ISGF3 complex (31,36,38). The binding of this complex to DNA is mediated by another member of the IRF family, ISGF3 $\gamma$ /p48, which in IFN-treated cells interacts with phosphorylated STAT1 and STAT2 transcription factors forming the heterotrimeric complex ISGF3 (8,39,62). The homozygous deletion of p48 in mice abolished the sensitivity of these mice to the antiviral effects of IFNs, and virus-infected macrophages from p48 $^{-/-}$  mice showed an impaired induction of IFNA and IFNB genes (31).

Several other members of the IRF family have been identified. The ICSBP gene is expressed exclusively in the cells of the immune system (18,64) and its expression can be enhanced by IFN $\gamma$ . ICSBP was shown to form a complex with IRF-1 and inhibit the transactivating activity of IRF-1 (9,59). The homozygous deletion of ICSBP in mice leads to defects in myeloid cell lineage development and chronic myelogenous leukemia (34). Another lymphoid specific Pip/LSIRF/IRF-4 was identified (19,43,66) that interacts with phosphorylated PU.1, a member of the Ets family of transcription factors (15). The Pip/PU.1 heterodimer can bind to the immunoglobulin light chain enhancer and function as a B cell specific transcriptional activator. Expression of Pip/LSIRF was induced by antigenic stimulation but not by IFN, and Pip/LSIRF/IRF-4  $^{-/-}$  mice failed to develop mature T and B cells (46). A novel member of the IRF family was recently identified by its ability to bind to an ISRE-like element in the promoter region of the Qp gene of EBV (69).

Another unique member of the human IRF family, IRF-3 was characterized recently (2). The IRF-3 gene encodes a 55-kDa protein which is expressed constitutively in all tissues. IRF-3 was originally identified as a member of the

IRF family based on homology with other IRF family members and on binding to the ISRE of the ISG15 promoter. The relative levels of IRF-3 mRNA do not change in virus-infected or IFN-treated cells. Recombinant IRF-3 binds to the ISRE element 5 of the IFN-induced gene ISG-15 and stimulates this promoter in transient expression assays. In previous studies, it has been shown that IRF-3 binds to the IE and PRDIII regions of the IFNA and IFNB promoters respectively, but has different effects on their transcriptional activity (56). While the induction of 10 the IFNA4 promoter activated by IRF-1 or virus infection was inhibited in the presence of IRF-3, the fusion protein containing the IRF-3 DNA binding domain and the RelA(p65) transactivation domain effectively activated both IFNA and IFNB promoters. In contrast, co-expression of IRF-3 and RelA 15 plasmids transactivated the IFNB gene promoter, but not the promoter of the IFNA4 gene (56).

Most of the IRF family members so far identified appear to have specific and critical functions in lymphoid cells and/or their action is related to the signalling pathway 20 induced by IFN or viruses. Interestingly, there is recent evidence indicating that the IRF(s) may also play a role in the transcriptional activation of viral promoters. The Qp promoter region of the EBV-encoded gene EBNA-1 contains an ISRE-like element that is responsive to the IRF-1 and IRF-2 as well as to 25 IFN- $\alpha$ . Using a yeast one-hybrid screen technique, a new factor was recently isolated that binds specifically to the Qp ISRE. The amino acid sequence of this protein is identical to the IRF-7 protein present in the Genbank database ((69); accession 30 number U73036). By homology search of the HGF ETS cDNA library the Pitha group has also identified a novel IRF whose sequence is identical to that of IRF-7. At the amino acid level, IRF-7 shows highest homology to IRF-3. Several open reading frames (ORFs) of IRF-7 have been identified. Pagano's group found three shorter ORFs, listed in the database as IRF-7A, B and C 35 ((69), accession nos. U53830, U53831 and U53832, respectively). A new IRF-7 isoform, IRF-7H, was recently identified by Pitha's group ((70), accession number AF076494).

In vitro translated IRF-7 encodes a protein of 68 kDa (69, 72). Interestingly, while in vitro translated IRF-7 protein binds effectively to the Qp ISRE, it doesn't seem to affect transcription of Qp-driven reporter constructs in a transient transcription assay (72). In contrast to IRF-3, IRF-7 expression is not generally constitutive but can be effectively induced by IFN- $\alpha$  in fibroblast cells, B-cells and other cells of lymphoid origin (70, 71). Like IRF-3, in uninfected cells, IRF-3 is present mainly in the cytoplasm, virus infection induced phosphorylation of IRF-7, resulting in cytoplasmic to nuclear translocation of phosphorylated IRF-7 and activated gene transcription (70, 71). Recent studies indicate that virus-stimulated phosphorylation of IRF-3 results in the activation of IFN $\alpha$ 4 and IFN $\beta$  gene transcription in murine cells. Once produced and secreted from the infected cell, IFN $\alpha$ 4 and IFN $\beta$  subsequently feed back on cells through the IFN receptor, stimulate the Jak-STAT pathway and lead to the IFN-responsive activation of another member of the IRF family - IRF-7; up-regulation of IRF-7 production then mediates the induction of non-IFN $\alpha$ 4 gene expression (71).

#### SUMMARY OF THE INVENTION

The present invention relates to IRF proteins that have been modified in the carboxy-terminus domain (transactivation domain) by modification of serine and/or threonine sites. Modification may be achieved by phosphorylation of serine and/or threonine, or by replacement of serine and/or threonine residues with residues having acidic side-chains, preferably carboxylic acid-containing side-chains, such as aspartic acid or glutamic acid residues. Such modified proteins may be mutants of IRF-3 and IRF-7, including chimeric proteins having portions of both IRF-3 and IRF-7, and post-translationally modified (phosphorylated) IRF-3 protein, the phosphorylation being induced by Sendai virus infection.

More specifically, the present invention provides a modified interferon regulatory factor (IRF) protein, the protein comprising at least one modified serine or threonine

76023-19

5

phosphoacceptor site in the carboxy-terminus domain, preferably wherein cytokine gene activation by the modified IRF is increased relative to cytokine gene activation by a corresponding wild type IRF protein.

5 The present invention also provides nucleotide sequences which encode a protein of the invention as described above. Such nucleotide sequences may, for example, be used to modify a target cell of an organism.

The present invention also provides a pharmaceutical composition comprising an effective amount of the interferon regulatory factor (IRF) protein according to the invention, together with a pharmaceutically acceptable carrier, for the treatment of a viral infection, for example, an influenza infection, a herpes infection, a hepatitis infection or an HIV infection.

The present invention also provides a commercial package containing the IRF protein or pharmaceutical composition according to the invention, together with instructions for its use for the treatment of cancer or of a viral infection, for example, an influenza infection, a herpes infection, a hepatitis infection or an HIV infection.

The present invention further provides use of the interferon regulatory factor (IRF) protein according to the invention to activate a cytokine gene, preferably wherein the cytokine gene is an interferon gene or a chemokine gene.

#### DESCRIPTION OF THE FIGURES

Figure 1. Sendai virus infection induces IRF-3 degradation. IRF-3 expression plasmid CMVBL-IRF3 (lanes 1 and 2) or CMVBL vector alone (lanes 3 and 4), both at 30 5 µg were transiently transfected into 293 cells by the calcium

76023-19

5a

AMT 34 AND 1  
phosphate method. At 24h post transfection, cells were infected with Sendai virus for 16h (lanes 2 and 4), or left uninfected (lanes 1 and 3). Whole cell extracts (20 µg) were prepared and analyzed by immunoblotting with anti-IRF-3 antibody.

Figure 2. Sendai virus induced phosphorylation and degradation of IRF-3 protein. A) rTA-IRF-3 cells, selected as described in Example, were induced to express IRF-3 by doxycycline treatment for 24h. At 24h after Dox addition, cells were infected with Sendai virus for 4, 8, 12, 16, 20, or 24h (lanes 2-7) or were left uninfected (lane 1). IRF-3 protein was detected in whole cell extracts (10 µg) by immunoblot. Two forms of IRF-3 were detected, designated as form I and form II. B) At 24h post Dox induction, rTA-IRF-3 cells were infected with Sendai virus for 16 hours (lanes 4-8) or were left uninfected (lanes 1-3). Whole cell extracts from untreated

cells (20 µg) or Sendai virus infected cells (60 µg) were incubated with 0.3 units of potato acidic phosphatase (PPA, lanes 2, 3, 7 and 8) or 5 units of calf intestinal alkaline phosphatase (CIP, lanes 4 and 5) in the absence (lanes 1, 2, 4, 5, 6 and 7) or presence of phosphatase inhibitors (lanes 3, 5 and 8). Phosphorylated IRF-3 protein appears as a distinct band in immunoblots, migrating more slowly than IRF-3 forms I and II.

Figure 3. Analysis of IRF-3 deletion mutants in Sendai virus induced phosphorylation.

- 10 (A) Schematic representation of four IRF-3 deletions. Thick solid lines and thin dashed lines indicate included and excluded sequences, respectively. The N-terminal IRF homology domain, the nuclear export signal (NES) and C-terminal IRF association domain are indicated.
- 15 (B) Expression plasmids (5 µg each) encoding wild type and deletion mutants of IRF-3 (as indicated above the lanes) were transiently transfected into 293 cells; at 24h post transfection, cells were infected with Sendai virus for 16h (lanes 2, 4, 6, 8, and 10) or left uninfected (lanes 1, 3, 5, 20 7, and 9). Whole cell extracts (20 µg) were prepared from infected and control cells and analyzed by immunoblotting for IRF-3 forms I and II and for the presence of phosphorylated IRF-3 (P-IRF-3) with anti-IRF-3 antibody.

Figure 4. Analysis of IRF-3 point mutations in Sendai virus induced phosphorylation.

- 25 (A) Schematic representation of IRF-3 point mutations. Thick solid lines and thin dashed lines indicate included and excluded sequences, respectively. The N-terminal IRF homology domain, the Nes element and C-terminal IRF association domain are indicated. Amino acids residues from 382 to 414 and from 30 141 to 147 are shown. The amino acids targeted for alanine or aspartic acid substitution are shown in large print. The point mutations are indicated below the sequence: (2A: S396A/S398A; 3A: S402A/T404A/S405A; 5A: S396A/S398A/S402A/T404A/S405A); 5D 35 S396D/S398D/S402D/T404D/S405D; J2A: S385A/S386A; NES: S145A/S146A).

(B) Expression plasmids (5 µg each) encoding wild type and

point mutants of IRF-3 (as indicated above the lanes) were transiently transfected into 293 cells; at 24h post transfection, cells were infected with Sendai virus for 16h (lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18) or left uninfected (lanes 1, 3, 5, 7, 9, 11, 13, 15 and 17). Whole cell extracts (20 µg) were prepared from infected and control cells and analyzed by immunoblotting for IRF-3 forms I and II and for the presence of phosphorylated IRF-3 (P-IRF-3) with anti-IRF-3 antibody.

Figure 5. Virus dependent cytoplasmic-nuclear translocation of IRF-3.

The subcellular localization of the GFP-IRF-3 (A and B), GFP-IRF-3(5A) (C and D), GFP-IRF-3(5D) (E and F) and GFP-IRF-3(NES) (G and H) was analyzed in uninfected (A, C, E, 15 and G) and Sendai virus infected COS-7 cells at 16h after infection. GFP fluorescence was analyzed in living cells with a Leica fluorescence microscope using 40x objective.

Figure 6. Transactivation of PRDI/PRDIII and ISRE containing promoters by IRF-3.

293 cells were transfected with IFN $\beta$ -CAT (A and B) or ISG15-CAT (C) reporter plasmids and the various expression plasmids as indicated below the bar graph. CAT activity was analyzed at 48h post-transfection with 100 µg (IFN $\beta$ -CAT) or 10 µg (ISG15-CAT) of total protein extract for 1-2h at 37°C. Relative CAT activity was measured as fold activation (relative to the basal level of reporter gene in the presence of CMV-Bl vector alone after normalization with co-transfected  $\beta$ -Gal activity); the values represent the average of three experiments with variability shown in the error bar.

Figure 7. IRF-3 inducible expression of RANTES gene.

(A) Stimulation of RANTES gene transcription in virus-infected and IRF-3(5D)-expressing cells. The rTTA, IRF-3 and IRF-3(5D) cells were cultured in the presence or absence of Dox as indicated. After 30 hours, cells were either left untreated, infected with Sendai virus (80HAU/ml) for 16 hours, or treated with IFN- $\alpha/\beta$  (100 IU/ml). The neutralizing antibody for type I IFN (Sigma) was added at the time of Dox addition.

Total RNA was isolated from each sample and analyzed by RPA using the hCK5 kit (Pharmingen).

(B) Repression of virus-induced RANTES gene transcription by a dominant-negative form of IRF-3. The rTTA- and 5 IRF-3(ΔN)-expressing cells were either left untrated or infected with Sendai virus (80 HAU/ml) for 16 hours. Total RNA was isolated from each sample and analyzed by RPA.

(C) The kinetics of RANTES expression induced by IRF-3 (5D). Total RNA from IRF-3(5D)-expressing cells was isolated 10 from each sample after Dox addition and analyzed by RPA.

(D) Cell culture supernatants were analyzed for the presence of RANTES protein by an ELISA performed as specified by the manufacturer (Biosource International).

Figure 8. Stabilization of IRF-3 by proteasome 15 inhibitors.

IRF-3 ΔN (Δ9-133) (B) or IRF-3 ΔN2A (C) expression plasmids were transiently transfected into 293 cells; at 24h post transfection, cells were infected with Sendai virus and treated for 12h with calpain inhibitor I (100 μM, lanes 2 and 20 5) or MG132 proteasome inhibitor (40 μM, lanes 3 and 6). Ethanol, the solvent for calpain inhibitor I and MG132, was added to the cells as control (lanes 1 and 4). Endogenous (A) and transfected (B and C) IRF-3 proteins were detected in whole cell extracts (20 μg) by immunoblot.

Figure 9. IRF-3 interacts with CBP in virus infected 25 cells.

(A) Schematic representation of CBP, illustrating the domains involved in interaction with host or viral proteins (modified from (28)) and the myc-tagged CBP proteins (CBP1, 30 CBP2, CBP3) used for immunoprecipitation.

(B) 293 cells were transfected with wild type and deletion mutants of IRF-3 expression plasmid (5 μg, as indicated above the lanes) or left untransfected (lanes 1 and 8). At 24h after transfection, cells were infected with Sendai virus for 16h 35 (lanes 1, 3-8, and 10-13) or left uninfected (lanes 1 and 9). Whole cell extracts (300 μg, except lane 1, which was 600 μg) were immunoprecipitated with anti-CBP antibody A22 (lanes 1-6)

or with preimmune serum (lane 7). The immunoprecipitated complexes (lanes 1-7) or 30 µg whole cell extracts (lanes 8-13) were run on 5% SDS-PAGE and subsequently probed with anti-IRF-3 antibody.

5 (C) 293 cells were co-transfected with myc-tagged CBP expression plasmids (as indicated above the lanes) and IRF-3 AN ( $\Delta$ 9-133) expression plasmid. At 24h after transfection, cells were infected with Sendai virus (lanes 2, 4 and 6) or left uninfected (lanes 1, 3 and 5). Whole cell extracts (300 µg) 10 were immunoprecipitated with monoclonal anti-myc-tag antibody 9E10. The immunoprecipitated complexes were run on 5% SDS-PAGE and different forms of IRF-3 in the precipitates were analyzed by immunoblotting with anti-IRF-3 antibody.

(D) Whole cell extracts (30 µg) from (C) were also 15 analyzed directly for the expression of myc-tagged CBP proteins by immunoblotting using anti-myc antibody 9E10.

Figure 10. The cDNA sequence encoding IRF-3(5D), together with the amino acid sequence of IRF-3(5D).

20 Figure 11. Transactivation study as described in Figure 6, using the IFN $\beta$ -CAT reporter plasmid to indicate the activity of various forms of IRF-3 and IRF-7 and binary mixtures thereof.

Figure 12. The cDNA sequence encoding IRF-7A(2D), together with the amino acid sequence of IRF-7A(2D).

25 Figure 13. The cDNA sequence encoding the IRF-7(1-246)/IRF-3(5D)(132-427) chimeric protein, together with the amino acid sequence of the IRF-7(1-246)/IRF-3(5D)(132-427) chimeric protein.

30 Figure 14. Transactivation study as described in Figure 6, using the IFN $\beta$ -CAT reporter plasmid to indicate the relative activity of various forms of IRF-3 and IRF-7, binary mixtures thereof and the chimeric protein IRF-7(1-246)/IRF-3(132-427) (IRF-7N-IRF-3(5D)C in Figure 14).

#### DETAILED DESCRIPTION OF THE INVENTION

35 As used herein, the term "nucleotide sequence" means a DNA or RNA molecule or sequence, and can include, for

example, a cDNA, genomic DNA, or synthetic DNA sequence, a structural gene or a fragment thereof, or an mRNA sequence, that encodes an active or functional polypeptide.

Two DNA, RNA or polypeptide sequences are

- 5 "substantially homologous" or "structurally equivalent" when there is at least about 85% (preferably at least about 90%, more preferably at least about 95%) identity between the nucleotides or amino acids over a defined length of the molecule. DNA sequences that are substantially homologous can  
10 be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Appropriate hybridization conditions are within the knowledge of a person skilled in the art. See, for example, Maniatis et al., Molecular Cloning, A Laboratory Manual. Cold  
15 Spring Harbour Laboratory, New York (1982); Brown, T. A., Gene Cloning: An Introduction (2nd Ed.) Chapman & Hall, London (1990).

The results disclosed herein show that phosphorylation represents an important post-translational  
20 modification of IRF-3 leading to cytoplasmic-to-nuclear translocation of phosphorylated IRF-3, stimulation of DNA binding and transcriptional activity, association of IRF-3 with the transcriptional co-activator CBP/p300, and ultimately proteasome mediated degradation.

25 More specifically, the results disclosed herein show that, following Sendai virus infection, IRF-3 may be post-translationally modified by protein phosphorylation at multiple serine and threonine residues, located in the carboxy-terminus of IRF-3.

30 Furthermore, while modification of functionally relevant (phosphoacceptor) serine and threonine sites may be by phosphorylation, the modification may also be a mutation represented by replacement of at least one of these functionally relevant serine or threonine residues with an  
35 amino acid having a carboxylic acid in its side chain, preferably aspartic acid or glutamic acid, more preferably aspartic acid. The preferred mutant form of IRF-3 is that

76023-19

11

ART 34 ANDT  
having aspartic acid residues in at least one of positions 396, 398, 402, 404 and 405 of the sequence, more preferably in positions 396, 398, 402, 404 and 405 of the sequence

(IRF-3(5D)) (Figure 10). The preferred mutant form of IRF-7 is 5 that having asparatic acid residues in at least one of positions 477 and 479 of the sequence, more preferable in positions 477 and 479 of the sequence (IRF-7(2D)) (Figure 12).

Also within the scope of the invention are chimeric proteins comprising a carboxy-terminus domain of one modified 10 IRF protein, modified as discussed above, and an amino-terminal domain of another IRF protein. Preferably, the amino-terminus of IRF-7 is fused to the carboxy-terminus of modified IRF-3. It is more preferred that the carboxy-terminus of modified 15 IRF-3 is that of IRF-3(5D). Even more preferred is a chimeric protein comprising residues 1 to 246 of IRF-7 and residues 132 to 427 of IRF-3(5D) (Figure 13).

Also within the scope of the invention are proteins which are substantially homologous to the above proteins and which retain the function of those proteins. This includes 20 proteins based on human IRF-3 and IRF-7, as well as corresponding IRF-3 and IRF-7 proteins of other species.

Nucleotide sequences within the scope of the invention are those which encode a protein of the invention. Preferably, the nucleotide sequence is a coding DNA sequence as 25 defined in Figure 10 or a DNA sequence which is hybridizable under stringent conditions with the complement of the coding DNA sequence of Figure 10, which DNA encodes IRF-3(5D). Also, preferably, the nucleotide sequence is a coding DNA sequence as defined in Figure 12 or a DNA sequence which is hybridizable 30 under stringent conditions with the complement of the coding DNA sequence in Figure 12, which DNA encodes IRF-7(2D). Also

76023-19

11a

*ART 34 AMDT*

preferably, the nucleotide sequence is a coding DNA sequence as defined in Figure 13 or a DNA sequence which is hybridizable under stringent conditions with the complement of the coding DNA sequence of Figure 13, which DNA encodes IRF-5 7(1-246)/IRF-3 (132-427) chimeric protein.

A combination of IRF-3 deletion and point mutations localized the inducible phosphorylation sites to the region -ISNSHPLSLTSDQ- between amino acids 395 and 407; point mutation

of Ser-396 and Ser-398 residues eliminated virus-induced phosphorylation of IRF-3 protein, although residues Ser-402, Thr-404 and Ser-405 were also targets. Phosphorylation results in the cytoplasmic to nuclear translocation of IRF-3, DNA binding and increased transcriptional activation. Substitution of the Ser/Thr sites with the phosphomimetic Asp generated a constitutively active form of IRF-3 that functioned as a very strong activator of promoters containing PRDI/PRDIII or ISRE regulatory elements. Use of phosphomimetic Glu for this purpose is also possible. Phosphorylation also appears to represent a signal for virus mediated degradation, since the virus induced turnover of IRF-3 was prevented by mutation of the IRF-3 Ser/Thr cluster or by proteasome inhibitors.

Interestingly, virus infection resulted in the association of IRF-3 with the CBP coactivator, as detected by co-immunoprecipitation with anti-CBP antibody, an interaction mediated by the C-terminal domains of both proteins. Mutation of the residues Ser-396 and Ser-398 in IRF-3 abrogated its binding to CBP. These results are discussed in terms of a model in which virus-inducible C-terminal phosphorylation of IRF-3 alters protein conformation to permit nuclear translocation, association with transcriptional partners and primary activation of IFN- and IFN-responsive genes.

Sendai virus dependent phosphorylation of IRF-3 was detected, occurring in a cluster of Ser and Thr sites in the carboxyl-terminal end of the protein. The residues implicated in this regulatory phosphorylation event are Ser-396/Ser-398/Ser-402/Thr-404/Ser-405, particularly the Ser-396/Ser-398 amino acids. 2) Phosphorylation of the IRF-3 in the Ser-Thr cluster resulted in the cytoplasmic to nuclear translocation of IRF-3; nuclear translocation was blocked by mutation of the phosphorylated amino acids. 3) Sendai virus infection induced the DNA binding and transactivation potential of IRF-3. Furthermore, IRF-3 containing the phosphomimetic Asp at the sites of C-terminal phosphorylation was an exceptionally strong transactivator of PRDI/PRDIII and ISRE containing promoters. 4) Phosphorylation was also required for the

association of IRF-3 with the CBP co-activator protein. 5) Sendai virus infection resulted in IRF-3 degradation; again, phosphorylation was required as a signal for inducer mediated degradation since mutation of Ser/Thr cluster also blocked 5 virus induced degradation.

Cytoplasmic to nuclear translocation of IRF-3 as a consequence of virus infection was inhibited by mutation of the Ser/Thr cluster, indicating an important regulatory role for C-terminal phosphorylation in the activation of IRF-3. Also 10 strikingly, the conversion of the phosphorylation sites to the phosphomimetic Asp altered the subcellular localization of IRF-3 in uninfected cells. A proportion of IRF-3(5D) was localized to the nucleus of uninfected cells, suggesting that some IRF-3 may shuttle to and from the nucleus constitutively; 15 this observation is consistent with the identification of a nuclear export signal in IRF-3. Mutation of L144A/L145A in the NES element produced the most impressive alterations in subcellular localization. In uninfected cells, IRF-3 was partitioned in both the nucleus and cytoplasm; virus infection 20 changed the nuclear pattern of staining from extra-nucleolar homogeneous staining as observed for wtIRF-3 to an intense nuclear speckling. At this stage, the nature of the subnuclear changes in IRF-3 localization are not explained, although it is possible that IRF-3(NES) translocates efficiently into the 25 nucleus but becomes trapped in the nuclear pore complex during the export process.

One of the striking results of the mutagenesis of the C-terminal domain of IRF-3 was the generation of IRF-3(5D), an exceptionally strong activator of IFN- $\beta$  and ISG-15 gene 30 expression. The phosphomimetic form of IRF-3 alone was able to stimulate IFN- $\beta$  expression as strongly as virus infection, a level of stimulation not previously observed in co-expression experiments (24,61). In previous experiments, it has been demonstrated that IRF-3 was able to bind the ISRE element of 35 ISG-15, as well as the PRDIII/PRDI and IE regions of the IFNB and IFNA promoters, respectively (2,56). Virus induction results in the appearance of two new protein-DNA complexes;

supershift experiments confirmed that both complexes contain IRF-3; it is not clear at this stage whether the upper complex also contains other proteins such as in the VIC (10,29) and DRAF (16) complexes or whether the lower complex represents a breakdown product of IRF-3. Strikingly, the same complexes appeared following co-transfection of IRF-3(5D) expression plasmid in the absence of virus induction, indicating that IRF-3(5D) represented a constitutive DNA binding form of IRF-3. Thus, in uninfected cells, IRF-3(5D) localized in part to the nucleus (Fig. 5), interacted with DNA constitutively and was a strong activator of gene expression (Fig. 6).

The recent crystal structure of the related IRF-1 protein bound to PRDI provides evidence for a novel helix-turn-helix motif that latches onto a GAAA core sequence via three of the five conserved tryptophan amino acids of the DNA binding domain (20). By analogy with IRF-3, two GAAANN sequences present in PRDIII of IFN- $\beta$  and another GAAANN element present in PRDI may serve as DNA contacts for multiple IRF-3(5D) proteins with strong activating potential.

Similarly, the ISRE element of the ISG-15 promoter also contains several GAAANN anchors for potential IRF binding. Given the range of promoters that possess this hexameric sequence (48), it will be of interest to determine the capacity of IRF-3(5D) to stimulate expression of different cytokine and chemokine genes.

IRF-3 joins a growing list of cellular and viral proteins that functionally interact with CBP/p300 proteins, highly homologous proteins originally identified through their interactions with adenovirus E1A and CREB proteins (1,13). As a critical determinant of its global transcriptional coactivator activity, CBP/p300 possesses histone acetyltransferase activity (5,50). Acetylation of histones is involved in the destabilization and remodelling of nucleosomes, a crucial step in permitting the accessibility of transcriptional factors to DNA templates. Several studies have now demonstrated that CBP/p300 participates in the transcriptional process by providing a scaffold for different

classes of transcriptional regulators on specific chromatin domains (12,50). A growing body of biochemical and genetic evidence also implicates CBP/p300 as a negative regulator of cell growth, based on its interactions with adenovirus Ela,  
5 SV40 large T antigen and the tumour suppressor p53, among others. With regard to p53-CBP/p300 complex formation, functional interaction between these two important growth regulatory proteins accounts for several of the known activities of p53 (3,28,40); interestingly, CBP/p300 was shown  
10 recently to acetylate p53 and stimulate its transactivation potential (27).

It will be of interest to determine whether IRF-3 is similarly modified by CBP association. The functional consequences of IRF-3 interaction with CBP/p300 remain to be  
15 elucidated, although recent studies demonstrated that CBP/p300 also functionally interacts with STAT 1 (68) and STAT 2 (7) and may contribute to IFN $\alpha$  and IFN $\gamma$  nuclear signalling. Recently published studies have demonstrated that synergistic activation of the IFN $\beta$  promoter requires recruitment of CBP/p300 to the  
20 enhanceosome, via a new activating surface assembled from the activation domains of all the transcription factors in the enhanceosome (37,45). Alterations in any of the activation domains decreased both CBP recruitment and transcriptional synergy. By analogy, recruitment of CBP/p300 to DNA bound  
25 IRF-3 is likely required for maximal transcriptional activation. Association requires the interaction of the C-terminal domain of IRF-3 and the C-terminal interaction domain of CBP, a region previously shown to associate with the p53 tumour suppressor, whereas STAT1 and STAT2 associate with  
30 different regions of CBP (7,68).

Virus induced phosphorylation of IRF-3 also represents a signal for proteasome mediated degradation of IRF-3, since mutation of the Ser-396/Ser-398 or the use of proteasome inhibitors prevented the post infection degradation  
35 of IRF-3. Virus induced degradation of IRF-3 is reminiscent of the virus-induced turnover of another member of the IRF family - IRF-2. In response to dsRNA or viral induction, the 50 kD

IRF-2 protein is proteolytically processed into a smaller, 24-27 kDa protein (51) comprising the 160 aa DBD of IRF-2, termed TH3 (14) or In4 (65). Although TH3 has been shown to bind DNA and repress transcription more efficiently than the 5 full length IRF-2 protein (42), its physiological role is not clear. Since the induction kinetics of TH3 are slower than that of IFN- $\beta$  in response to dsRNA or viral infection (14), it has been suggested that the IRF-2 cleavage product may be a post-induction repressor of IFN- $\beta$  gene expression (65).

10           Virus induced phosphorylation of IRF-3 at the C-terminal Ser/Thr residues and its subsequent degradation by a proteasome dependent pathway are also similar to the well studied phosphorylation and degradation of I $\kappa$ B $\alpha$  which leads to activation of NF- $\kappa$ B binding activity (reviewed in 4,6). In 15 unstimulated cells, NF- $\kappa$ B heterodimers are retained in the cytoplasm by inhibitory I $\kappa$ B proteins. Upon stimulation by many activating agents, including cytokines, viruses and dsRNA, I $\kappa$ B $\alpha$  is rapidly phosphorylated and degraded, resulting in the release and nuclear translocation of NF- $\kappa$ B. The amino-terminus 20 of I $\kappa$ B $\alpha$  represents a signal response domain for activation of NF- $\kappa$ B and substitution of alanine for either Ser-32 or Ser-36 completely abolished the signal-induced phosphorylation and degradation of I $\kappa$ B $\alpha$ , and blocked the activation of NF- $\kappa$ B. These mutations also blocked *in vitro* ubiquitination of the 25 I $\kappa$ B $\alpha$  protein. The amino-terminus of I $\kappa$ B $\alpha$  is necessary for signal-induced phosphorylation and ubiquitination, but for degradation to occur, there is an absolute requirement for the C-terminal PEST domain (reviewed in 4,6).

Similarities and differences exist between the 30 observed degradation of IRF-3 and the mechanism of I $\kappa$ B $\alpha$  degradation. The C-terminal phosphorylation of IRF-3 as a consequence of virus infection is required for its subsequent degradation based on the deletion and point mutation analysis of the region -ISNSHPLSLTSDQ- between amino acids 395 and 407. 35 Minimally, phosphorylation of Ser-396 and Ser-398 are required for subsequent degradation, although Ser-402, Ser-404 and Ser-405 may represent secondary phosphorylation sites.

Likewise, in the case of I $\kappa$ B $\alpha$ , phosphorylation and Ser-32 and Ser-36 are required for inducer mediated degradation.

Furthermore, the protease inhibitor calpain inhibitor I and the more specific proteasome inhibitor MG132 block IRF-3 turnover.

5 A major difference in the mechanisms of I $\kappa$ B $\alpha$  and IRF-3 turnover lies in the nature of the inducing stimuli. Multiple inducers - cytokines such as TNF and IL-1, viruses, LPS, oxidative stress, etc (6) - all lead to the induction of I $\kappa$ B $\alpha$  phosphorylation and degradation whereas IRF-3  
10 phosphorylation appears to be induced only by virus infection and dsRNA addition; other inducers have not resulted in IRF-3 turnover.

A significant temporal difference also exists between I $\kappa$ B $\alpha$  phosphorylation/turnover and IRF-3  
15 phosphorylation/degradation. Many activators of NF- $\kappa$ B stimulate I $\kappa$ B $\alpha$  phosphorylation within minutes and TNF induced degradation occurs within the first 15-30 minute after treatment. In the case of IRF-3, phosphorylation is not detected until 6-8 hours after infection and continues in a  
20 heterogenous manner over the next 10-12 hours. Previous experiments have, however, demonstrated that Sendai virus-induced turnover of I $\kappa$ B $\alpha$  also occurs slowly over several hours (24).

Based on the data presented herein and by analogy  
25 with the properties of other IRF family members (48), the following model is proposed to explain several observations. IRF-3 exists in a latent state in the cytoplasm of uninfected cells; the C-terminus may physically interact with the DNA binding domain in such a way as to obscure both the DBD and the  
30 IAD regions of the protein; the presence of an autoinhibitory domain within the C-terminal 20aa (407-427) would explain the activating effect of this deletion, as seen previously with IRF-4 (11,19). Virus induced phosphorylation at the Ser/Thr at 396-405aa cluster leads to a conformational change in IRF-3,  
35 exposing both the DBD and IAD and relieving C-terminal autoinhibition. Translocation to the nucleus, occurring via an

unidentified nuclear localization sequence or in conjunction with a transcriptional partner associating through the IAD region, leads to DNA binding at ISRE- and PRDI/PRDIII-containing promoters. Phosphorylation is also necessary for IRF-3 association with the chromatin remodelling activity of CBP/p300. The presence of a NES element ultimately shuttles IRF-3 from the nucleus and terminates the initial activation of IFN responsive promoters. The phosphorylated form of IRF-3 exported from the nucleus may now be susceptible to proteasome mediated degradation. This scenario shares several features with the protein synthesis independent activation of NF- $\kappa$ B, and further suggests that IRF-3 may represent a component of virus- or dsRNA-inducible complexes such as DRAF (16) or VIC (10,29) that could play a primary role in the induction of IFN- or IFN responsive genes.

In view of the above-mentioned properties, and in particular its ability to stimulate an immune response, IRF protein is useful as a tumour suppressor.

The invention is described in more detail in the following examples.

Example 1: Plasmid constructions and Mutagenesis.

The IRF-3 expression plasmid was prepared by cloning the EcoRI-XhoI fragment containing the IRF-3 cDNA from the pSKIRF-3 plasmid downstream of the CMV promoter of CMVBL vector. CMVt-IRF-3 was constructed by cloning of IRF-3 cDNA downstream of the doxycycline-responsive promoter CMVt at the BamHI site of the neo CMVt BL vector (49). cDNAs encoding IRF-3 carboxyl terminal deletion mutations were generated by 28 cycles of PCR amplification with Vent DNA polymerase. DNA oligonucleotide primers were synthesized using an Applied Biosystems DNA/RNA synthesizer. The amino-terminal primer was synthesized with an EcoRI restriction enzyme site and the carboxyl-terminal primers were synthesized with XbaI restriction enzyme sites at their ends. The PCR products were purified by phenol/chloroform extraction and ethanol precipitation, digested with EcoRI and XbaI, and inserted into EcoRI/XbaI sites of CMVBL vector.

The point mutations of IRF-3 were generated by overlap PCR mutagenesis using Vent DNA polymerase. Mutations were confirmed by sequencing.

The N-terminal deletion mutations ( $\Delta N$ ,  $\Delta N2A$ ,  $\Delta N3A$  and  $\Delta N5A$ ) of IRF-3 were generated by digestion of the related IRF-3/CMVBL plasmid with *Bam*HI (filled in with Klenow enzyme), partial digestion with *Sca*I, and re-ligation. GFP-IRF-3 expression plasmids were generated by cloning of cDNAs encoding wild type or mutated forms of IRF-3 into the downstream of EGFP in the pEGFP-C1 vector (Clonetech). For construction of plasmids encoding myc-tagged CBP truncated proteins, the cDNAs coding for CBP were generated from the pRC-RSV/mCBP plasmid (provided by Dr. Dimitris Thanos) by PCR amplification. The cDNA fragments were cloned in the downstream of myc-tag in 5' myc-PCDNA3 vector (provided by Dr. Stephane Richard).

For the construction of pFlag-IRF-7, the IRF-7 cDNA was created by PCR and the resulting product was cloned into pFlag CMV-2 vector. To generate the IRF-7(aa1-246)-IRF-3(5D)(aa132-427) chimera, the cDNA encoding IRF-3 (5D) (aa132-427) was cut out from IRF-3 (5D)/CMVBL plasmid with *Sca*I and *Not*I (blunted with Klenow enzyme) and was cloned into pFlag-IRF-7 (digested with *Sma*I, which removed the C-terminal region of IRF-7 from 247-503) in frame with the IRF-7 N-terminal amino acid sequence (1-246). The point mutations of IRF-7 (D477-D479) were generated by overlap PCR mutagenesis essentially as described above for IRF-3 using Vent DNA polymerase. Codon AGC encoding residues Ser 477 and Ser 479 were mutated to GAC (Asp). Mutations were confirmed by sequencing.

Example 2: Generation of IRF-3 cell lines.

Plasmid CMVt-rtTA (49) was introduced into 293 cells by a calcium phosphate-based method. Cells were selected beginning at 48h after transfection for about one week in  $\alpha$ MEM media (GIBCO-BRL) containing 10% heat-inactivated calf serum, glutamine, antibiotics and 2.5 ng/ $\mu$ l puromycin (Sigma). Resistant cells carrying the CMVt-rtTA plasmid (rtTA-293 cells) were then transfected with the CMVt-IRF-3 plasmid. Cells were selected beginning at 48h for a period of approximately 2 weeks

in  $\alpha$ MEM containing 10% heat-inactivated calf serum, glutamine, antibiotics, 2.5 ng/ $\mu$ l puromycin and 400  $\mu$ g/ml G418 (Life Technologies, Inc.).

Example 3: Cell culture and transfections.

5 All transfections for CAT assay were carried out in human embryonic kidney 293 cells or NIH3T3 cells grown in  $\alpha$ MEM (293) or Dulbecco's MEM (NIH3T3) media (GIBCO-BRL) supplemented with 10% calf serum, glutamine and antibiotics. Subconfluent cells were transfected with 5  $\mu$ g of CsCl purified  
10 chloramphenicol acetyltransferase (CAT) reporter and expression plasmids by calcium phosphate coprecipitation method (293 cells) or lipofectamine (NIH3T3 cells). The reporter plasmids were the SV $\beta$  CAT and ISG15 CAT reporter genes (56); also the transfection procedures were previously described (41,56). For  
15 individual transfections, 100  $\mu$ g (SV $\beta$  CAT) or 10  $\mu$ g (ISG15 CAT) of total protein extract was assayed for 1-2h at 37°C. The CAT activity was normalized with  $\beta$ -Gal assay. All transfections were performed 3-6 times.

Example 4: Western blot analysis of IRF-3 modification and degradation.

To characterize the posttranslational regulation of IRF-3 protein, stable or transiently transfected IRF-3 expressing cells were infected with Sendai Virus (80 HAU/ml) or treated with 5 ng/ml TNF- $\alpha$ , either with or without addition of  
25 50  $\mu$ g/ml cycloheximide. In some experiments, cells were treated with either 100  $\mu$ M calpain inhibitor I (ICN), 40  $\mu$ M MG132 proteasome inhibitor, or an equivalent volume of their respective solvent (ethanol) as control. Cells were washed with phosphate-buffered saline and lysed in 10 mM Tris-Cl pH  
30 8.0, 200 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 0.5% Nonidet P-40 (NP-40), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 5  $\mu$ g/ml leupeptin, 5  $\mu$ g/ml pepstatin, and 5  $\mu$ g/ml aprotinin. Equivalent amounts of whole cell extract (20  $\mu$ g) were subject to SDS-polyacrylamide gel electrophoresis  
35 (SDS-PAGE) in a 10% polyacrylamide gel. After electrophoresis, the proteins were transferred to Hybond transfer membrane (Amersham) in a buffer containing 30 mM Tris, 200 mM glycine

and 20% methanol for 1h. The membrane was blocked by incubation in phosphate-buffered saline (PBS) containing 5% dried milk for 1h and then probed with IRF-3 antibody in 5% milk/PBS, at a dilution of 1:3000. These incubations were done  
5 at 4°C overnight or at RT for 1-3h. After four 10 minute washes with PBS, membranes were reacted with a peroxidase-conjugated secondary goat anti-rabbit antibody (Amersham) at a dilution of 1:2500. The reaction was then visualized with the enhanced chemiluminescence detection system (ECL) as recommended by the  
10 manufacturer (Amersham Corp.).

Example 5: Phosphatase treatment.

Twenty to sixty  $\mu$ g of whole cell extract were treated with 0.3 units of potato acidic phosphatase (Sigma) in a final volume of 30  $\mu$ l PIPES buffer (10 mM PIPES pH 6.0, 0.5 mM PMSF,  
15 5  $\mu$ g/ml aprotinin, 1  $\mu$ g/ml leupeptin, and 1  $\mu$ g/ml pepstatin) or 5 units of calf intestine alkaline phosphatase (Pharmacia) in 30  $\mu$ l CIP buffer. The phosphatase inhibitor mix contained 10 mM NaF, 1.5 mM Na<sub>2</sub>MoO<sub>4</sub>, 1 mM  $\beta$ -glycerophosphate, 0.4 mM Na<sub>3</sub>VO<sub>4</sub> and 0.1  $\mu$ g/ml okadaic acid.

20 Example 6: Subcellular localization of GFP-IRF-3 proteins.

To analyse the subcellular localization of wild type and mutated forms of IRF-3 proteins in uninfected and virus infected cells, the GFP-IRF-3 expression plasmids (5  $\mu$ g) were transiently transfected into COS-7 cells by the calcium phosphate coprecipitation method. For virus infection, transfected cells were infected with Sendai virus (80 hemagglutinating units per mL for 2h) at 24h post transfection. GFP fluorescence was analyzed in living cells with a Leica fluorescence microscope using a 40x objective.  
25

30 Example 7: Electromobility Shift Assay.

Nuclear extracts were prepared from 293 cells at different times after infection with Sendai virus (80 HAU/ml). In some experiments, extracts were prepared from cells transfected with different IRF-3 expression plasmids, as  
35 indicated in individual experiments. Cells were washed in Buffer A [10 mM HEPES, pH 7.9; 1.5 mM MgCl<sub>2</sub>; 10 mM KCl; 0.5 mM dithiothreitol (DTT); and 0.5 mM phenylmethylsulfonyl fluoride

- (PMSF)] and were resuspended in Buffer A containing 0.1% NP-40. Cells were then chilled on ice for 10 minutes before centrifugation at 10,000 g. Pellets were then resuspended in Buffer B (20mM HEPES, pH 7.9; 25% glycerol; 0.42 M NaCl; 1.5 mM 5 MgCl<sub>2</sub>; 0.2 mM EDTA; 0.5 mM DTT; 0.5 mM PMSF; 5 µg/ml leupeptin; 5 µg/ml pepstatin; 0.5 mM spermidine; 0.15 mM spermine; and 5 µg/ml aprotinin). Samples were incubated on ice for 15 minutes before being centrifuged at 10,000 g. Nuclear extract supernatants were diluted with Buffer C (20 mM HEPES, pH 7.9; 10 20% glycerol; 0.2 mM EDTA; 50 mM KCl; 0.5 mM DTT; and 0.5 mM PMSF). Nuclear extracts were subjected to EMSA by using a 32P-labelled probe corresponding to the PRDIII region of the IFN-β promoter (5'-GGAAAAGTCAAAGGG-3') or the ISRE region of the ISG-15 promoter (5'-GATCGGGAAAGGGAAACCGAAACTGAAGCC-3'). 15 The resulting protein-DNA complexes were resolved by 5% polyacrylamide gel and exposed to X-ray film. To demonstrate the specificity of protein-DNA complex formation, 125-fold molar excess of unlabelled oligonucleotide was added to the nuclear extract before adding labelled probe.
- 20 Example 8: Immunoprecipitation and Western analysis of CBP associated proteins.

Whole cell extract (300 µg) were prepared from either transfected or untransfected cells and precleared with 5 µl of preimmune rabbit serum and 20 µl of protein A-Sepharose beads 25 (Pharmacia) for 1 hour at 4°C. The extract was incubated with 10 µl of anti-CBP antibody A-22 (Santa Cruz) or 2 µl anti-myc antibody 9E10 (21) and 30 µl of protein A-Sepharose beads for 2-3 hours at 4°C. Precipitates were washed 5 times with lysis buffer, eluted by boiling the beads 3 minutes in 1x SDS sample 30 buffer. Eluted proteins were separated by SDS PAGE, transferred to Hybond transfer membrane. Membranes were incubated with anti-IRF-3 (1:3000) or anti-myc antibody 9E10 (1:1000). Immunocomplexes were detected by using a chemiluminescence-based system.

35 The results of the above examples are summarized below.

Virus induced phosphorylation of IRF-3 protein.

IRF-3 is expressed constitutively in various cells and its expression is not enhanced by viral infection or by IFN treatment. To investigate whether the IRF-3 protein is regulated by post-translational modification after virus infection, 293 cells were transiently transfected with an IRF-3 expression plasmid and subsequently infected with Sendai virus 24h later. In cells transfected with CMVBL vector alone, endogenous IRF-3 protein was easily detected using a polyclonal IRF-3 antibody and in cells transfected with the IRF-3 expression plasmid, IRF-3 protein levels were significantly increased (Fig.1, lanes 1 and 3). Interestingly, Sendai virus infection resulted in two alterations in the expression of IRF-3: 1) an overall decrease in the amount of IRF-3 in transfected and control cells (Fig. 1, lanes 2 and 4) and the generation of a more slowly migrating form of IRF-3 (Fig. 1, compare lanes 1 and 2). In all experiments, the turnover of IRF-3 after virus infection was more pronounced with the endogenous protein than with the transfected proteins (see Fig.1, as well as others). Because the transfected proteins were driven by the CMV promoter, ongoing synthesis of transfected IRF-3 may partially obscure the turnover of IRF-3.

The kinetics of virus-induced modification of IRF-3 were characterized in a 293 cell line that expressed IRF-3 inducibly under the control of the tetracycline responsive promoter CMVt (25,26). Infection of this cell line (designated rtTA-IRF-3) with Sendai virus resulted in a decrease in the amount of IRF-3 between 12 and 24h after infection (Fig. 2A). Two forms of IRF-3 protein (designated I and II) were detected in uninfected cells (Fig. 2A, lane 1) and following virus infection, a third slowly migrating form of IRF-3 was also detected (Fig.2A, lanes 4-7). To determine whether the slowest form of IRF-3 was due to virus-induced phosphorylation (P-IRF-3), the different forms of IRF-3 were subjected to treatment in vitro with potato acidic phosphatase (PPA) or calf intestine alkaline phosphatase (CIP) and/or phosphatase inhibitors (Fig. 2B). These treatments did not affect the

mobilities of forms I and II in uninfected cells (Fig. 2B, lanes 1-3). However, in rtTA-IRF-3 expressing 293 cells infected with Sendai virus for 12h, an additional slowly migrating, presumably phosphorylated form of IRF-3 was also detected (Fig. 2B, lane 6); this form of IRF-3 completely disappeared following CIP or PPA treatment (Fig. 2B, lanes 6 and 7) but was maintained in the presence of CIP/PPA when phosphatase inhibitors were also added to the reaction (Fig. 2B, lanes 5 and 8).

10 Mapping the IRF-3 phosphorylation sites.

A series of deletions of IRF-3 were generated to identify the virus-induced phosphorylation site(s) of IRF-3 (Fig. 3A). 293 cells were transiently transfected with IRF-3 deletion mutants and the virus mediated phosphorylation was measured by immunoblotting (Fig. 3B). The results indicated that a virus-induced phosphorylation of IRF-3 occurs at the C-terminal end of IRF-3 since the mutations that contained only the N-terminal part of IRF-3 protein (133, 240, 328, 357 or 394aa) were not phosphorylated (Fig. 3B). Full length and 20 407aa forms of IRF-3 were phosphorylated as a consequence of virus infection (Fig. 3B, lanes 1-4). C-terminal truncation of IRF-3 to a protein of 394 or 357aa removed the site(s) of inducible phosphorylation (Fig. 3B, lanes 5-8), although the shortened versions of forms I and II were still observed. Also 25 in the IRF-3 Δ9-133 mutation (ΔN) which had the DNA binding, N-terminal amino acids (aa9 to aa133) removed, both virus induced phosphorylation of IRF-3 and the differential migration of the shortened forms I and II were easily detected (Fig. 3B, lanes 9 and 10). Degradation of the endogenous forms of IRF-3 30 by virus infection was also detected in this experiment (compare Fig. 3B, lanes 7 and 9 with lanes 8 and 10).

Thus, by deletion analysis, a phosphorylation domain of IRF-3 protein was localized to the region -ISNSHPLSLTSDQ- between amino acids 395 and 407. Point mutations in the 35 several putative Ser and Thr phosphorylation residues within this region were generated in the full length protein and the Δ9-133 (ΔN) protein (Fig. 4A). In the IRF-3 cDNA encoding

these proteins, the Ser-396/Ser398/Ser-402/Thr-404/Ser-405 residues were replaced by alanine (5A), as were the three residues Ser-402/Thr-404/Ser-405 (3A) and the two residues Ser-396/Ser-398 (2A). Transfection of these plasmids into 293  
5 cells and subsequent virus infection revealed that full length wild type IRF-3 was phosphorylated (Fig. 4B, lanes 4 and 8), whereas the IRF-3 proteins containing 2A and 5A mutations were no longer phosphorylated in virus infected cells (Fig. 4B,  
10 lanes 6 and 10). Interestingly, IRF-3-3A was also very weakly phosphorylated as a consequence of virus infection, thus implicating Ser-402/Thr-404/Ser-405 as potential secondary sites of phosphorylation. Using the ΔN IRF-3 protein and the relevant point mutations, phosphorylation was detected with ΔN  
15 (Fig. 4B, lane 12) but not with ΔN-2A and ΔN-5A (Fig. 4B, lanes 14 and 18); likewise, ΔN-3A displayed very weak phosphorylation (Fig. 4B, lane 16).

These experiments thus implicate Ser-396 and Ser-398 as critical sites of virus-induced phosphorylation of IRF-3; however, Ser-402/Thr-404/Ser-405 residues also contribute to  
20 the observed phosphorylation, since the migration of phosphorylated ΔN-3A is significantly faster than ΔN and the phosphorylation level is decreased (Fig. 4B, lanes 12 and 16). Another study suggested the involvement of the Ser residues at aa385 and 386 as potential phosphoacceptor sites (67).  
25 However, in studies with the S385A/S386A mutation, no evidence was found for inducible phosphorylation at these sites. Nevertheless, since these sites represent consensus sites for CKI and CKII, constitutive phosphorylation is a possibility.  
30 IRF-3 phosphorylation induces cytoplasmic to nuclear translocation of IRF-3.

Initial studies indicated that IRF-3 was localized in the cytoplasm of uninfected cells (67); to investigate the role of phosphorylation on IRF-3 localization, wild type and point mutated forms of IRF-3 were linked to green fluorescent protein  
35 (GFP), transfected into COS-7 cells and examined for Sendai virus induced changes in subcellular localization (Fig. 5). In uninfected cells, GFP-IRF-3 localized exclusively to the

cytoplasm; Sendai virus infection resulted in translocation of IRF-3 to the nucleus within 8h in 90-95% of the cells (Fig. 5A and B). Mutation of the Ser/Thr cluster in GFP-IRF-3 (5A) completely abrogated virus-induced cytoplasmic to nuclear translocation (Fig. 5, C and D). Interestingly, the substitution of the Ser/Thr cluster with the phosphomimetic Asp in GFP-IRF-3 (5D) likewise altered subcellular localization. IRF-3 (5D) localized both to the nucleus and cytoplasm in uninfected cells (Fig. 5E), while virus infection resulted in an intense nuclear pattern of IRF-3 (5D) fluorescence (Fig. 5F). Point mutation of a putative nuclear export signal in IRF-3, the L145A/L146A modification - termed IRF-3 (NES) - also changed subcellular localization of IRF-3. In uninfected cells, GFP-IRF-3 (NES) was localized to the nucleus and cytoplasm, with a homogeneous, extra-nucleolar pattern of nuclear staining. After virus infection, GFP-IRF-3 (NES) localized to the nucleus with an intense speckled pattern of nuclear fluorescence in greater than 95% of the cells, suggesting that IRF-3 (NES) may be trapped in the nucleus associated with the nuclear pore complex.

Transactivation of PRDI/PRDIII and ISRE promoters by IRF-3.

Next, the capacity of IRF-3 to regulate gene expression was analysed by transient transfection in human 293 and murine NIH3T3 cells using the IFN $\beta$  and ISG-15 promoters in reporter gene assays. Expression of NF- $\kappa$ B RelA(p65), IRF-1 and IRF-3 alone minimally induced IFN $\beta$  promoter activity between 3 to 4 fold (Fig. 6A and B), as shown previously (24,56,61). Introduction of the C-terminal point mutants - IRF-3 (2A), IRF-3 (3A) IRF-3 (5A) - reduced the low transactivation capacity of IRF-3 to control levels (Fig. 6A). Interestingly, deletion of the C-terminal 20aa of IRF-3 to IRF-3 (407) stimulated IFN $\beta$  activity about 6 fold, indicative of the removal of an inhibitory domain in IRF-3. However, further deletion to 394, 357 or 240 abrogated transactivation potential (Fig. 6A). Mutation of the NES element was not sufficient to stimulate IFN $\beta$  activity. Strikingly, the substitution of the Ser/Thr cluster at aa397-405 in IRF-3 with the phosphomimetic Asp

generated a very strong, constitutive transactivator protein that alone stimulated the IFN $\beta$  promoter 90 fold.

As shown previously, high level induction of the IFN $\beta$  promoter requires synergistic activation by NF- $\kappa$ B and IRF proteins (24,61). To analyse the properties of IRF-3 in synergistic activation of the IFN $\beta$  promoter, co-expression studies were performed using RelA(p65) expression plasmid and different wild type and mutant forms of IRF-3 (Fig. 6B).

Co-expression of RelA and IRF-1 or RelA and IRF-3 stimulated IFN $\beta$ -CAT activity by 20-25 fold. IRF-3(407) and RelA(p65) stimulated IFN $\beta$  activity about 40 fold, supporting the idea of the removal of an inhibitory domain in IRF-3, whereas both the IRF-3(394) and the IRF-3(NES) failed to synergise with RelA in the activation of the IFN $\beta$  promoter. RelA and IRF-3(NES) produced a relatively weak 8 fold induction of IFN $\beta$  expression, indicating that nuclear localization is not sufficient for IRF-3 activation. The combination of RelA and IRF-3(5D) produced an 80 fold stimulation of IFN $\beta$  promoter activity (Fig. 6B); together with the above data, IRF-3(5D) alone appears to be capable of full stimulation of the IFN $\beta$  promoter and further synergy with RelA is not observed (compare Fig. 6A and B). Surprisingly, IRF-3(5A) and RelA produced a 30 fold stimulation, suggesting that 5A can still synergise with RelA, despite mutation of the Ser/Thr cluster.

The transactivation potential of IRF-3 was also analysed using the ISG-15 promoter, an ISRE containing regulatory element (Fig. 6C). As shown previously (2), and above for the IFN $\beta$  promoter, IRF-3 alone weakly activated the ISG-15 promoter; in the context of this regulatory element, IRF-3 was weaker than IRF-1, which produced a 9 fold stimulation. Again deletion of the C-terminal 20aa of IRF-3 generated a protein that stimulated gene expression; with the ISG-15 promoter, a 12 fold induction was observed; IRF-3(394) and IRF-3(357) did not stimulate gene expression but rather slightly repressed ISG-15. Again remarkably, IRF-3(5D) produced a 50 fold induction of the ISG-15 promoter (Fig. 6C), thus demonstrating that substitution of the Ser/Thr sites with

the phosphomimetic Asp generated a constitutively active form of IRF-3 that functioned as a very strong activator of promoters containing PRDI/PRDIII or ISRE regulatory elements.

Activation of RANTES Transcription by IRF-3 and Virus

Chemokine expression is demonstrated in Figure 7, the chemokine being RANTES (Regulated on Activation Normal T-cell Expressed and Secreted) protein. IRF-3-inducible cells were used to determine whether other cytokine-chemokine genes may be regulated by IRF-3; an (Rnase Protection Analysis (RPA) with multiple human cytokine-chemokine probes (Pharmingen) was used to examine RNA derived from rtTA-IRF-3 or rtTA-IRF-3(5D) cells. Strikingly, the RANTES gene was highly expressed in the IRF-3(5D)-inducible cells, as well as in virus-infected cells (Fig. 7A, lanes 3, 5, and 7) but not in uninfected rtTA- or wt IRF-3-expressing cells (Fig. 7A, lanes 1 and 4). Since IRF-3(5D) was a strong transactivator of the IFN- $\beta$  promoter in transient transfection assays, the possibility of an autoregulatory effect of IFN- $\alpha/\beta$  expression on transcription of RANTES promoter via JAK-STAT activation was considered. Activation of RANTES did not occur secondary to the production of IFN- $\alpha/\beta$ , since RANTES mRNA was not detected in control rtTA-expressing cells treated directly with IFN- $\alpha/\beta$  (Fig. 7A, lane 2); furthermore, addition of neutralizing antibody directed against type I IFN did not block the stimulation of RANTES gene expression by IRF-3(5D) (Fig. 7A, lane 8). Other experiments also demonstrated that IRF-3 itself was not activated by IFN treatment (13a). Inducible expression of RANTES in cells stably expressing a dominant-negative form of IRF-3 which lacks the N-terminal amino acids 9 to 133 and does not bind to DNA was also examined. As shown in Fig. 7B, RANTES gene transcription was induced by Sendai virus in control (rtTA) cells (Fig. 7B) but not in IRF-3 ( $\Delta N$ )-expressing cells (Fig. 7B). This experiment indicates that a non-DNA binding, dominant-negative mutant of IRF-3 is able to block completely virus-induced activation of RANTES transcription.

The kinetics of IRF-3 transgene induction and RANTES mRNA expression were characterized at various times following

Dox induction. IRF-3(5D) was detected at 8 to 12 hours with peak levels at 24 hours following Dox addition. RANTES mRNA was first detectable at 18 hours after Dox induction with peak levels at 40 hours (Fig. 7C, lanes 5 to 10). Induction of RANTES protein expression as detected by ELISA (Fig. 7D) was first observed at 12 hours after Dox induction of IRF-3, in good agreement with the mRNA levels, and accumulated thereafter with a dramatic increase between 24 and 32 hours after stimulation, also in agreement with mRNA levels. The possibility that IRF-3(5D) may be directly activating another transcription factor such as NF- $\kappa$ B, which in turn would stimulate RANTES transcription, was also considered. No evidence for IRF-3(5D)-mediated activation of NF- $\kappa$ B DNA binding activity was observed. Similarly, IRF-3(5D) expression did not activate the human immunodeficiency virus (HIV)-long terminal repeat, a complex promoter controlled by NF- $\kappa$ B and other transcription factors (data not shown).

Inhibition of IRF-3 degradation.

Another consequence of virus infection is the degradation of the IRF-3. Since phosphorylation of proteins is functionally associated with the process of protein degradation via the ubiquitin-dependent proteasome pathway (53,57,60), the effect of proteasome inhibitors on virus-induced turnover of IRF-3 was examined. In cells transfected with the  $\Delta$ N and  $\Delta$ N5A forms of IRF-3, virus induced degradation of full length (endogenous) forms of IRF-3 (Fig. 8A, lanes 1 and 4) and the truncated  $\Delta$ N (Fig. 8B, lanes 1 and 4) was detected. Addition of the protease inhibitor calpain inhibitor I or the proteasome inhibitor MG132 blocked virus-induced IRF-3 degradation (Fig. 8A and 8B, lanes 4-6). Particularly with the  $\Delta$ N protein, the accumulation of the phosphorylated form of  $\Delta$ N was also detected in virus infected cells (Fig. 8B, lanes 5 and 6), suggesting that phosphorylation of IRF-3 may represent a signal for subsequent degradation by the proteasome pathway. To confirm this idea, the 5A point mutated form of IRF-3 was analysed; the IRF-3- $\Delta$ N5A protein was resistant to virus induced degradation (Fig. 8C, lanes 1 and 4); no further stabilization of

IRF-3-ΔN5A occurred with calpain inhibitor I or MG132 addition and no phosphorylated IRF-3 was detected (Fig. 8C, lanes 4-6). These experiments demonstrate that virus dependent phosphorylation of the C-terminal of IRF-3 represents a signal 5 for subsequent proteasome mediated degradation.

Interaction between IRF-3 and CBP in virus infected cells.

To examine the possibility that IRF-3 associated with the co-activator CBP/p300 (Fig. 9A) following Sendai virus infection, CBP was immunoprecipitated from virus-infected cells 10 with anti-CBP antibody; an immunoblot for IRF-3 revealed that IRF-3 was co-precipitated from virus-infected cells but not from uninfected cells (Fig. 9B, lanes 2 and 3). This interaction was observed clearly in cells co-transfected with the IRF-3 expression plasmid (Fig. 9B, lane 3 ) but was not 15 seen when the immunoprecipitation was performed with pre-immune serum (Fig. 9B, lane 7). The endogenous IRF-3 also co-precipitated from virus-infected cells (Fig. 9B, lane 1). However, mutation of the Ser/Thr residues identified as the virus inducible phosphorylation sites abrogated the association 20 of IRF-3 with CBP. In particular, IRF-3(2A) and IRF-3(5A) were detected in whole cell extract immunoblot but not in the CBP immunoprecipitate (Fig. 9B, compare lanes 4 and 6 with lanes 11 and 13). With the IRF-3(3A) mutant, interaction with CBP was still observed (Fig. 9B, lane 5). The high background in all 25 lanes represents secondary antibody reactivity with rabbit IgG from the immunoprecipitation. Immunoblot analysis of the whole cell extracts revealed that phosphorylated IRF-3, as well as forms I and II were present in virus infected cells (Fig. 9B, lane 10) and in cells transfected with 2A, 3A and 5A the forms 30 I and II were observed but not the phosphorylated form of IRF-3 (Fig. 9B, lanes 11-13).

CBP has several domains that bind transcription factors, designated CBP1, CBP2, and CBP3 respectively (Fig. 9A, reviewed in (28)). To determine which domain of CBP interacts 35 with IRF-3, the three specific subdomains were myc-tagged at the 5' end by subcloning into the pCDNA3 vector (Fig. 9A). 293 cells were co-transfected with these myc-tagged CBP expression

plasmids together with the IRF-3 ΔN (Δ9-133) expression plasmid. At 24h after transfection, cells were infected with Sendai virus, co-immunoprecipitated with anti-myc antibody 16h later (21) and then immunoblotted for IRF-3. Endogenous IRF-3 and transfected IRF-3 ΔN proteins co-precipitated with CBP-3 from virus-infected cells but not from uninfected cells (Fig. 9C, lane 6). In cells co-transfected with CBP-1 and CBP-2, no endogenous or transfected ΔN IRF-3 was detected (Fig. 9C, lanes 1-4). Immunoblot analysis of the whole cell extracts revealed that all three myc-tagged CBP proteins were efficiently expressed in uninfected and virus infected cells (Fig. 9D). These results demonstrate that IRF-3 binds to the C-terminal domain of CBP in virus infected cells and interaction with CBP requires Ser-396/Ser-398 phosphorylation of IRF-3 but not at Ser-402/Thr-404/Ser-405.

Figure 11 shows the relative activity of various forms of IRF-3 and IRF-7, and binary mixtures thereof, in transactivation studies. Both the IRF-3(5D) and IRF-7(2D) mutants show increased activity relative to their corresponding wild-type proteins. There is a synergistic effect present when both proteins are present, and this effect is most pronounced in a mixture of the IRF-3(5D) and IRF-7(2D) (D477/479) mutants.

Figure 14 shows that the chimeric protein IRF-7(1-246)/IRF-3(5D) (132-427) has a markedly increased activity over the mixture of the IRF-3(5D) and IRF-7(2D) (D477/479) mutants.

A pharmaceutical composition may be prepared, with a protein of the invention as active ingredient, for the treatment of a viral infection, such as an influenza infection, a herpes infection or an HIV infection.

The pharmaceutical compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, transdermal (e.g., patch), intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal

administration or in a form suitable for administration by inhalation or insufflation.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycollate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).

For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.

The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.

Alternatively, the active ingredient may be in powder form for

reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The active compounds of the invention may also be formulated in rectal compositions such as suppositories or 5 retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension 10 from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon 15 dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from 20 gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

The protein of the invention can also be made available using gene therapy. The DNA encoding the protein can 25 be introduced to cells of an organism at a target site, for example, by a viral vector, by electroporation, by co-transfection with a selectable marker, or by DNA vaccine.

#### REFERENCES

1. Arany, Z., Sellers, W.R., Livingston, D.M. and Eckner, R. 30 1994. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. *Cell* 77:799-800.
2. Au, W.-C., Moore, P.A., Lowther, W., Juang, Y.-T. and Pitha, P.M. 1995. Identification of a member of the interferon regulatory factor family that binds to the 35 interferon-stimulated response element and activates expression

of interferon-induced genes. Proc.Natl.Acad.Sci.USA  
92:11657-11661.

3. Avantaggiati, M.L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A.S. and Kelly, K. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89:1175-1184.
4. Baldwin, A.S.Jr. 1996. The NF- $\kappa$ B and I $\kappa$ B proteins: new discoveries and insights. Annu.Rev.Immunol. 14:649-681.
5. Bannister, A.J. and Kouzarides, T. 1996. The CBP coactivator is a histone acetyltransferase. Nature  
10 384:641-643.
6. Beauparlant, P. and Hiscott, J. 1996. Biological and biochemical inhibitors of the NF- $\kappa$ B/Rel proteins and cytokine synthesis. CytGrowthFactRev 7:175-190.
7. Bhattacharya, S., Eckner, R., Grossman, S., Oldread, E., Arany, Z., D'Andrea, A. and Livingston, D.M. 1996. Cooperation of Stat2 and p300/CBP by interferon- $\alpha$ . Nature  
15 383:344-347.
8. Bluyssen, H.A.R., Durbin, J.E. and Levy, D.E. 1996. ISGF3 $\gamma$  p48, a specificity switch for interferon activated transcription factors. CytGrowthFactRev 7:11-17.
9. Bovolenta, C., Driggers, P.H., Marks, M.S., Medin, J.A., Politis, A.D., Vogel, S.N., Levy, D.E., Sakaguchi, K., Appella, E., Coligan, J.E. and Ozato, K. 1994. Molecular interactions between interferon consensus sequence binding protein and  
20 members of the interferon regulatory factor family. Proc.Natl.Acad.Sci.USA 91:5046-5050.
10. Bragança, J., Génin, P., Bandu, M.-T., Darracq, N., Vignal, M., Cassé, C., Doly, J. and Civitas, A. 1997. Synergism between multiple virus-induced-factor-binding elements involved in the  
25 differential expression of IFN-A genes. J.Biol.Chem. 272:  
22154-22162.
11. Brass, A.L., Kehrli, E., Eisenbeis, C.F., Storb, U. and Singh, H. 1996. Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and  
30 ternary complex formation with the Ets factor PU.1. Genes Dev.  
10:2335-2347.

12. Chen, H., Lin, R.J., Schiltz, R.L., Chakravarti, D., Nash, A., Nagy, L., Privalsky, M.L., Nakatani, Y. and Evans, R.M. 1997. Nuclear receptor coactivator ACTR is a novel histone acetyltransferases and forms a multimeric activation complex with P/CAF and CBP/p300. *Cell* 90:569-580.
13. Chrivia, J.C., Kwok, R.P.S., Lamb, N., Hagiwara, M., Montminy, M.R. and Goodman, R.H. 1993. Phosphorylated CREB binds specifically to the nuclear protein CBP. *Nature* 365:855-859.
- 10 14. Cohen, L. and Hiscott, J. 1992. Characterization of TH3, an induction specific protein interacting with the interferon- $\beta$  promoter. *Virol.* 191:589-599.
- 15 15. Crepieux, P., Coll, J. and Stehelin, D. 1994. The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners. *CritRevOncogen* 5:615-638.
16. Daly, C. and Reich, N.C. 1993. Double-stranded RNA activates novel factors that bind to the interferon stimulated response element. *Mol.Cell.Biol.* 13:3756-3764.
17. Darnell Jr., J.E., Kerr, I.M. and Stark, G.R. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 264:1415-1421.
- 20 18. Driggers, P.H., Ennist, D.L., Gleason, S.L., Mak, W.-H., Marks, M.S., Levi, B.-Z., Flanagan, J.R., Appella, E. and Ozato, K. 1990. An interferon  $\gamma$ -regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. *Proc.Natl.Acad.Sci.USA* 87:3743-3747.
- 25 19. Eisenbeis, C.F., Singh, H. and Storb, U. 1995. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. *Genes Dev.* 9:1377-1387.
20. Escalante, C.R., Yie, J., Thanos, D. and Aggarwal, A.K. 1998. Structure of IRF-1 with bound DNA reveals determinants of interferon regulation. *Nature* 391:103-106.
- 35 21. Evan, G.I. and Bishop, J.M. 1985. Isolation of monoclonal antibodies specific for the human c-myc proto-oncogene product. *Mol.Cell.Biol.* 4:2843-2850.

22. Fujita, T., Kimura, Y., Miyamoto, M., Barsoumian, E.L. and Taniguchi, T. 1989. Induction of endogenous IFN- $\alpha$  and IFN- $\beta$  genes by a regulatory transcription factor IRF-1. *Nature* 337:270-272.
- 5 23. Fujita, T., Sakakibara, J., Sudo, Y., Miyamoto, M., Kimura, Y. and Taniguchi, T. 1988. Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN- $\beta$  gene regulatory elements. *EMBO J.* 7:3397-3405.
24. Garoufalidis, E., Kwan, I., Lin, R., Mustafa, A., Pepin, N.,
- 10 Roulston, A., Lacoste, J. and Hiscott, J. 1994. Viral induction of the human interferon  $\beta$  promoter: modulation of transcription by NF- $\kappa$ B/rel proteins and interferon regulatory factors. *J.Virol.* 68:4707-4715.
- 15 25. Gossen, M. and Bujard, H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc.Natl.Acad.Sci.USA* 89:5547-5551.
26. Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W. and Bujard, H. 1995. Transcriptional activation by tetracyclines in mammalian cells. *Science* 268:1766-1769.
- 20 27. Gu, W. and Roeder, R.G. 1997. Activation of p53 sequence-specific DNA binding by acetylation of p53 C-terminal domain. *Cell* 90:595-606.
28. Gu, W., Shi, X.L. and Roeder, R.G. 1997. Synergistic activation of transcription by CBP and p53. *Nature*
- 25 387:819-823.
29. Génin, P., Bragança, J., Darracq, N., Doly, J. and Civats, A. 1995. A novel PRDI and TG binding activity involved in virus-induced transcription of IFN-A genes. *NuclAcidRes* 23:5055-5063.
30. 30. Harada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M., Furia, A., Miyata, T. and Taniguchi, T. 1989. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. *Cell* 58:729-739.
- 35 31. Harada, H., Matsumoto, M., Sato, M., Kashiwazaki, Y., Kimura, T., Kitagawa, M., Yokochi, T., Tan, R.S.-P., Takasugi, T., Kadokawa, Y., Schindler, C., Schreiber, R.D., Noguchi, S.

- and Taniguchi, T. 1996. Regulation of IFN- $\alpha/\beta$  genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN- $\alpha/\beta$ . *Genestocells* 1:995-1005.
- 5 32. Harada, H., Willison, K., Sakakibara, J., Miyamoto, M., Fujita, T. and Taniguchi, T. 1990. Absence of type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. *Cell* 63:903-913.
- 10 33. Hiscott, J., Nguyen, H. and Lin, R. 1995. Molecular mechanisms of interferon  $\beta$  gene induction. *SeminVirol* 6:161-173.
34. Holtschke, T., Löhler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobeloch, K.-P., Gabriele, L.,
- 15 Waring, J.F., Bachmann, M.F., Zingernagel, R.M., Morse III, H.C., Ozato, K. and Horak, I. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. *Cell* 87:307-317.
35. Ihle, J.N. 1996. STATs: signal transducers and
- 20 activators of transcription. *Cell* 84:331-334.
36. Kawakami, T., Matsumoto, M., Sato, M., Harada, H., Taniguchi, T. and Kitigawa, M. 1995. Possible involvement of the transcription factor ISGF3 $\gamma$  in virus-induced expression of the IFN- $\beta$  gene. *FEBS Lett.* 358:225-229.
- 25 37. Kim, T.K. and Maniatis, T. 1998. The mechanism of transcriptional synergy of an in vitro assembled interferon  $\beta$  enhanceosome. *Mol.Cell* 1:119-129.
38. Kimura, T., Kadokawa, Y., Harada, H., Matsumoto, M., Sato, M., Kashiwazaki, Y., Tarutani, M., Tan, R.S-P., Takasugi, T.,
- 30 Matsuyama, T., Mak, T.M., Noguchi, S. and Taniguchi, T. 1996. Essential and non-redundant roles of p48 (ISGF3 $\gamma$ ) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. *Genestocells* 1:115-124.
39. Levy, D.E. 1995. Interferon induction of gene expression
- 35 through the Jak-Stat pathway. *SeminVirol* 6:181-190.

40. Lill, N.L., Grossman, S.R., Ginsberg, D., DeCaprio, J. and Livingston, D.M. 1997. Binding and modulation of p53 by p300/CBP coactivators. *Nature* 387:823-827.
41. Lin, R., Beauparlant, P., Makris, C., Meloche, S. and Hiscott, J. 1996. Phosphorylation of I $\kappa$ B $\alpha$  in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability. *Mol.Cell.Biol.* 16:1401-1409.
42. Lin, R., Mustafa, A., Nguyen, H. and Hiscott, J. 1994. Mutational analysis of interferon (IFN) regulatory factors 1 and 2: Effects on the induction of IFN- $\beta$  gene expression. *J.Biol.Chem.* 269:17542-17549.
43. Matsuyama, T., Grossman, A., Mittrucker, H.-W., Siderovski, D.P., Kiefer, F., Kawakami, T., Richardson, C.D., Taniguchi, T., Yoshinaga, S.K. and Mak, T.W. 1995. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). *NuclAcidRes* 23:2127-2136.
44. Matsuyama, T., Kimura, T., Kitagawa, M., Watanabe, N., Kundig, T., Amakawa, R., Kishihara, K., Wakeham, A., Potter, J., Furlonger, C., Narendran, A., Suzuki, H., Ohashi, P., Paige, C., Taniguchi, T. and Mak, T. 1993. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN induction and aberrant lymphocyte development. *Cell* 75:83-97.
45. Merika, M., Williams, A., Chen, G., Collins, T. and Thanos, D. 1998. Recruitment of CBP/p300 by the IFN $\beta$  enhanceosome is required for synergistic activation of transcription. *Mol.Cell* 1:277-287.
46. Mittrucker, H.-W., Matsuyama, T., Grossman, A., Kundig, T.M., Potter, J., Shahinian, A., Wakeham, A., Patterson, B., Ohashi, P.S. and Mak, T.W. 1997. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. *Science* 275:540-543.
47. Miyamoto, M., Fujita, T., Kimura, Y., Maruyama, M., Harada, H., Sudo, Y., Miyata, T. and Taniguchi, T. 1988. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to the IFN- $\beta$  gene regulatory elements. *Cell* 54:903-913.

48. Nguyen, H., Hiscott, J. and Pitha, P.M. 1997. The growing family of IRF transcription factors. *CytGrowthFactRev* 8:in press.
49. Nguyen, H., Lin, R. and Hiscott, J. 1997. Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. *Oncogene* 15:1425-1435.
50. Ogryzko, V.V., Schiltz, R.L., Russanova, V., Howard, B.H. and Nakatani, Y. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell* 87:953-959.
- 10 51. Palombella, V. and Maniatis, T. 1992. Inducible processing of interferon regulatory factor-2. *Mol.Cell.Biol.* 12:3325-3336.
52. Pitha, P.M. and Au, W.-C. 1995. Induction of interferon  $\alpha$  gene expression. *SeminVirol* 6:151-159.
- 15 53. Read, M.A., Neish, A.S., Luscinskas, F.W., Palombella, V.J., Maniatis, T. and Collins, T. 1995. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. *Immunity* 2:493-506.
54. Reis, L.F.L., Harada, H., Wolchok, J.D., Taniguchi, T. and Vilcek, J. 1992. Critical role of a common transcription factor, IRF-1, in the regulation of IFN- $\beta$  and IFN-inducible genes. *EMBO J.* 11:185-193.
- 20 55. Russo, J.J., Bohenzky, R.A., Chien, M.-C., Chen, J., Yan, M., Maddalena, D., Parry, J.P., Peruzzi, D., Edelman, I.S., Chang, Y. and Moore, P. 1996. Nucleotide sequence of the kaposi sarcoma-associated herpesvirus (HHV8). *Proc.Natl.Acad.Sci.USA* 93:14862-14867.
56. Schafer, S., Lin, R., Moore, P., Hiscott, J. and Pitha, P.M. 1998. Regulation of type 1 interferon gene expression by interferon regulatory factor 3. *J.Biol.Chem.* 273:2714-2720.
- 30 57. Scherer, D.C., Brockman, J.A., Chen, Z., Maniatis, T. and Ballard, D.W. 1995. Signal-induced degradation of  $I\kappa B\alpha$  requires site-specific ubiquitination. *Proc.Natl.Acad.Sci.USA* 92:11259-11263.
- 35 58. Schindler, C. and Darnell Jr., J.E. 1995. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. *Ann.Rev.Biochem.* 64:621-651.

59. Sharf, R., Meraro, D., Azriel, A., Thornton, A.M., Ozato, K., Petricoin, E.F., Larner, A.C., Schaper, F., Hauser, H. and Levi, B.-Z. 1997. Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact  
5 with interferon regulatory factors and to bind DNA.  
*J.Biol.Chem.* 272:9785-9792.
60. Thanos, D. and Maniatis, T. 1995. NF- $\kappa$ B: a lesson in family values. *Cell* 80:529-532.
61. Thanos, D. and Maniatis, T. 1995. Identification of the  
10 rel family members required for virus induction of the human  $\beta$  interferon gene. *MolCellBiol* 15:152-164.
62. Veals, S.A., Schindler, C., Leonard, D., Fu, X.-Y., Aebersold, R., Darnell Jr., J.E. and Levy, D.E. 1992. Subunit of an  $\alpha$ -interferon-responsive transcription factor is related  
15 to interferon regulatory factor and myb families of DNA-binding proteins. *MolCellBiol* 12:3315-3324.
63. Vilcek, J. and Sen, G. Interferons and other cytokines. In: *Virology*, edited by Fields, B., Knipe, D.M. and Howley, P.M. Philadelphia: Lippincott-Raven, 1996, p. 375-399.
- 20 64. Weisz, A., Marx, P., Sharf, R., Appella, E., Driggers, P.H., Ozato, K. and Levi, B.-Z. 1992. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes.  
*J.Biol.Chem.* 267:25589-25596.
- 25 65. Whiteside, S.T., King, P. and Goodbourn, S. 1994. A truncated form of the IRF-2 transcription factor has the properties of a postinduction repressor of interferon- $\beta$  gene expression. *J.Biol.Chem.* 269:27059-27065.
66. Yamagata, T., Nishida, J., Tanaka, T., Sakai, R., Mitani,  
30 K., Yoshida, M., Taniguchi, T., Yazaki, Y. and Hirai, H. 1996. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. *MolCellBiol* 16:1283-1294.
67. Yoneyama, M., Suhara, W., Fukuhara, Y. and Fujita, T.  
35 1997. Direct activation of a factor complex composed of IRF-3 and CBP/p300 by virus infection. *J.Interferon Cytokine Res.*  
17:S53.

68. Zhang, J.J., Vinkemeier, U., Gu, W., Chakravarti, D.,  
Horvath, C.M. and Darnell, J.E. 1996. Two contact regions  
between STAT1 and CBP/p300 in interferon  $\gamma$  signalling.  
*Proc.Natl.Acad.Sci.USA* 93:15092-15096.
- 5 69. Zhang, L. and Pagano, J.S. 1997. IRF-7, a new interferon  
regulatory factor associated with Epstein Barr Virus latency.  
*Mol.Cell.Biol.* 17:5748-5757.
70. Au, W.C., Moore, P.A., LaFleur, D.W., Tombal, B. and  
Pitha, P.M. (1998). Characterization of the interferon  
10 regulatory factor-7 and its potential role in the transcription  
activation of interferon A gene. *J. Biol. Chem.* 273, 29210-  
29217.
71. Marie, I., Durbin, J.B. and Levy, D.E. (1998).  
Differential viral induction of distinct interferon- $\alpha$  genes by  
15 positive feedback through interferon regulatory factor-7. *EMBO J.* 17, 6660-6669.
72. Nonkwelllo C, Ruf IK, Sample J. 1997. Interferon-  
independent and -induced regulation of Epstein-Barr Virus EBNA-  
1 gene transcription in Burkitt lymphoma. *J. Virol.* 71, 6887-  
20 6897.

09/647965

PCT/CA99/00314

528 Rec'd PCT/PTO 06 OCT 2000

WO 99/51737

1/13

SEQUENCE LISTING

<110> THE SIR MORTIMER B. DAVIS-JEWISH GENERAL HOSPITAL

<120> HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR

PROTEINS

<130> IRF-3

<140>

<141>

<150> CA 2,234,588

<151> 1998-04-07

<160> 11

<170> PatentIn Ver. 2.0

<210> 1

<211> 1284

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1281)

<400> 1

atg gga acc cca aag cca cgg atc ctg ccc tgg ctg gtg tcg cag ctg 48  
Met Gly Thr Pro Lys Pro Arg Ile Leu Pro Trp Leu Val Ser Gln Leu  
1 5 10 15

gac ctg ggg caa ctg gag ggc gtg gcc tgg gtg aac aag agc cgc acg 96  
Asp Leu Gly Gln Leu Glu Gly Val Ala Trp Val Asn Lys Ser Arg Thr  
20 25 30

cgc ttc cgc atc cct tgg aag cac ggc cta cgg cag gat gca cag cag 144  
Arg Phe Arg Ile Pro Trp Lys His Gly Leu Arg Gln Asp Ala Gln Gln  
35 40 45

gag gat ttc gga atc ttc cag gcc tgg gcc gag gcc act ggt gca tat 192  
Glu Asp Phe Gly Ile Phe Gln Ala Trp Ala Glu Ala Thr Gly Ala Tyr  
50 55 60

gtt ccc ggg agg gat aag cca gac ctg cca acc tgg aag agg aat ttc 240  
Val Pro Gly Arg Asp Lys Pro Asp Leu Pro Thr Trp Lys Arg Asn Phe  
65 70 75 80

2/13

cgc tct gcc ctc aac cgc aaa gaa ggg ttg cgt tta gca gag gac cg	288
Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu Arg Leu Ala Glu Asp Arg	
85 90 95	
agc aag gac cct cac gac cca cat aaa atc tac gag ttt gtg aac tca	336
Ser Lys Asp Pro His Asp Pro His Lys Ile Tyr Glu Phe Val Asn Ser	
100 105 110	
gga gtt ggg gac ttt tcc cag cca gac acc tct ccg gac acc aat ggt	384
Gly Val Gly Asp Phe Ser Gln Pro Asp Thr Ser Pro Asp Thr Asn Gly	
115 120 125	
gga ggc agt act tct gat acc cag gaa gac att ctg gat gag tta ctg	432
Gly Gly Ser Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu	
130 135 140	
ggg aac atg gtg ttg gcc cca ctc cca gat ccg gga ccc cca agc ctg	480
Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu	
145 150 155 160	
gct gta gcc cct gag ccc tgc cct cag ccc ctg ccg agc ccc agc ttg	528
Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Ile Arg Ser Pro Ser Leu	
165 170 175	
gac aat ccc act ccc ttc cca aac ctg ggg ccc tct gag aac cca ctg	576
Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn Pro Ile	
180 185 190	
aag cgg ctg ttg gtg ccg ggg gaa gag tgg gag ttc gag gtg aca gcc	624
Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu Val Thr Ala	
195 200 205	
tcc tac cgg ggc cgc caa gtc ttc cag cag acc atc tcc tgc ccg gag	672
Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser Cys Pro Glu	
210 215 220	
ggc ctg cgg ctg gtg ggg tcc gaa gtg gga gac agg acg ctg cct gga	720
Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr Leu Pro Gly	
225 230 235	
tgg cca gtc aca ctg cca gac cct ggc atg tcc ctg aca gac agg gga	768
Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr Asp Arg Gly	
240 245 250 255	
gtg atg agc tac gtg agg cat gtg ctg agc tgc ctg ggt ggg gga ctg	816
Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly Gly Leu	
260 265 270	
gct ctc tgg cgg gcc ggg cag tgg ctc tgg gcc cag ccg ctg ggg cac	864
Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg Leu Gly His	
275 280 285	
tgc cac aca tac tgg gca gtg agc gag gag ctg ctc ccc aac agc ggg	912
Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro Asn Ser Gly	
290 295 300	
cat ggg cct gat ggc gag gtc ccc aag gac aag gaa gga ggc gtg ttt	960
His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly Gly Val Phe	
305 310 315	
gac ctg ggg ccc ttc att gta gat ctg att acc ttc acg gaa gga agc	1008
Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr Glu Gly Ser	
320 325 330 335	
gga cgc tca cca cgc tat gcc ctc tgg ttc tgt gtg ggg gag tca tgg	1056
Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly Glu Ser Trp	
340 345 350	

3/13

ccc cag gac cag ccg tgg acc aag agg ctc gtg atg gtc aag gtt gtg	1104
Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val Lys Val Val	
355 360 365	
ccc acg tgc ctc agg gcc ttg gta gaa atg gcc cggt gta ggg ggt gcc	1152
Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val Gly Gly Ala	
370 375 380	
tcc tcc ctg gag aat act gtg gac ctg cac att gac aac gac cac cca	1200
Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn Asp His Pro	
385 390 395	
ctc gac ctc gac gac cag tac aag gcc tac ctg cag gac ttg gtg	1248
Leu Asp Leu Asp Asp Asp Gln Tyr Lys Ala Tyr Leu Gln Asp Leu Val	
400 405 410 415	
gag ggc atg gat ttc cag ggc cct ggg gag agc tga	1284
Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser	
420 425	

&lt;210&gt; 2

&lt;211&gt; 427

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Gly Thr Pro Lys Pro Arg Ile Leu Pro Trp Leu Val Ser Gln Leu	
1 5 10 15	

Asp Leu Gly Gln Leu Glu Gly Val Ala Trp Val Asn Lys Ser Arg Thr	
20 25 30	

Arg Phe Arg Ile Pro Trp Lys His Gly Leu Arg Gln Asp Ala Gln Gln	
35 40 45	

Glu Asp Phe Gly Ile Phe Gln Ala Trp Ala Glu Ala Thr Gly Ala Tyr	
50 55 60	

Val Pro Gly Arg Asp Lys Pro Asp Leu Pro Thr Trp Lys Arg Asn Phe	
65 70 75	

Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu Arg Leu Ala Glu Asp Arg	
80 85 90 95	

Ser Lys Asp Pro His Asp Pro His Lys Ile Tyr Glu Phe Val Asn Ser	
100 105 110	

Gly Val Gly Asp Phe Ser Gln Pro Asp Thr Ser Pro Asp Thr Asn Gly	
115 120 125	

Gly Gly Ser Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu	
130 135 140	

Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu	
145 150 155	

Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser Pro Ser Leu	
160 165 170 175	

Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn Pro Leu	
180 185 190	

4/13

Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu Val Thr Ala  
195 200 205

Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser Cys Pro Glu  
210 215 220

Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr Leu Pro Gly  
225 230 235

Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr Asp Arg Gly  
240 245 250 255

Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly Gly Leu  
260 265 270

Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg Leu Gly His  
275 280 285

Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro Asn Ser Gly  
290 295 300

His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly Gly Val Phe  
305 310 315

Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr Glu Gly Ser  
320 325 330 335

Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly Glu Ser Trp  
340 345 350

Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val Lys Val Val  
355 360 365

Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val Gly Gly Ala  
370 375 380

Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn Asp His Pro  
385 390 395

Leu Asp Leu Asp Asp Asp Gln Tyr Lys Ala Tyr Leu Gln Asp Leu Val  
400 405 410 415

Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser  
420 425

&lt;210&gt; 3

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

<400> 3  
Ile Ser Asn Ser His Pro Leu Ser Leu Thr Ser Asp Gln  
1 5 10

&lt;210&gt; 4

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

5/13

Gly Ala Ala Ala  
1

<210> 5

<211> 6

<212> PRT

<213> Homo sapiens

<400> 5

Gly Ala Ala Ala Asn Asn  
1 5

<210> 6

<211> 15

<212> DNA

<213> Homo sapiens

<400> 6

ggaaaaactga aaggg

15

<210> 7

<211> 30

<212> DNA

<213> Homo sapiens

<400> 7

gatcggggaaa gggaaaccgaa aactgaagcc

30

<210> 8

<211> 1512

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1509)

<400> 8

atg gcc ttg gct cct gag agg gca gcc cca cgc gtg ctg ttc gga gag 48  
Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu  
1 5 10 15

tgg ctc ctt gga gag atc agc agc ggc tgc tat gag ggg ctg cag tgg 96  
Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp  
20 25 30

6/13

ctg gac gag gcc cgc acc tgt ttc cgc gtg ccc tgg aag cac ttc gcg Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala	35	40	45	144
cgc aag gac ctg agc gag gcc gac gcg cgc atc ttc aag gcc tgg gct Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala	50	55	60	192
gtg gcc cgc ggc agg tgg ccg cct agc agc agg gga ggt ggc ccc Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Pro Pro	65	70	75	240
ccc gag gct gag act gcg gag cgc gcc ggc tgg aaa acc aac ttc cgc Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg	85	90	95	288
tgc gca ctg cgc agc acg cgt cgc ttc gtg atg ctg cgg gat aac tcg Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser	100	105	110	336
ggg gac ccg gcc gac ccg cac aag gtg tac gcg ctc agc cgg gag ctg Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu	115	120	125	384
tgc tgg cga gaa ggc cca ggc acg gac cag act gag gca gag gcc ccc Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro	130	135	140	432
gca gct gtc cca cca cca cag ggt ggg ccc cca ggg cca ttc ttg gca Ala Ala Val Pro Pro Gln Gly Pro Pro Gly Pro Phe Leu Ala	145	150	155	480
cac aca cat gct gga ctc caa gcc cca ggc ccc ctc cct gcc cca gct His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala	165	170	175	528
ggt gac aag ggg gac ctc ctc cag gca gtgcaa cag agc tgc ctg Gly Asp Lys Gly Asp Leu Leu Gln Ala Val Gln Gln Ser Cys Leu	180	185	190	576
gca gac cat ctg ctg aca gcg tca tgg ggg gca gat cca gtc cca acc Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr	195	200	205	624
aag gct cct gga gag gga caa gaa ggg ctt ccc ctg act ggg gcc tgt Lys Ala Pro Gly Glu Gly Leu Pro Leu Thr Gly Ala Cys	210	215	220	672
gct gga ggc cca ggg ctc cct gct ggg gag ctg tac ggg tgg gca gta Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val	225	230	235	720
gag acg acc ccc agc ccc ggg ccc cag ccc gcg gca cta acg aca ggc Glu Thr Thr Pro Ser Pro Gly Pro Gln Pro Ala Ala Leu Thr Thr Gly	245	250	255	768
gag gcc ggc gcc cca gag tcc ccg cac cag gca gag ccg tac ctg tca Glu Ala Ala Ala Pro Glu Ser Pro His Gln Ala Glu Pro Tyr Leu Ser	260	265	270	816
ccc tcc cca agc gcc tgc acc gcg gtg caa gag ccc agc cca ggg gcg Pro Ser Pro Ser Ala Cys Thr Ala Val Gln Glu Pro Ser Pro Gly Ala	275	280	285	864
ctg gac gtg acc atc atg tac aag ggc cgc acg gtg ctg cag aag gtg Leu Asp Val Thr Ile Met Tyr Lys Gly Arg Thr Val Leu Gln Lys Val	290	295	300	912

7/13

gtg gga cac ccg agc tgc acg ttc cta tac ggc ccc cca gac cca gct Val Gly His Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp Pro Ala 305 310 315 320	960
gtc cgg gcc aca gac ccc cag cag gta gca ttc ccc agc cct gcc gag Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe Pro Ser Pro Ala Glu 325 330 335	1008
ctc ccg gac cag aag cag ctg cgc tac acg gag gaa ctg ctg cgg cac Leu Pro Asp Gln Lys Gln Leu Arg Tyr Thr Glu Glu Leu Arg His 340 345 350	1056
gtg gcc cct ggg ttg cac ctg gag ctt cgg ggg cca cag ctg tgg gcc Val Ala Pro Gly Leu His Leu Glu Leu Arg Gly Pro Gln Leu Trp Ala 355 360 365	1104
cgg cgc atg ggc aag tgc aag gtg tac tgg gag gtg ggc gga ccc cca Arg Arg Met Gly Lys Cys Lys Val Tyr Trp Glu Val Gly Pro Pro 370 375 380	1152
ggc tcc gcc agc ccc tcc acc cca gcc tgc ctg ctg cct cgg aac tgt Gly Ser Ala Ser Pro Ser Thr Pro Ala Cys Leu Leu Pro Arg Asn Cys 385 390 395 400	1200
gac acc ccc atc ttc gac ttc aga gtc ttc ttc caa gag ctg gtg gaa Asp Thr Pro Ile Phe Asp Phe Arg Val Phe Phe Gln Glu Leu Val Glu 405 410 415	1248
ttc cgg gca cgg cag cgc cgt ggc tcc cca cgc tat acc atc tac ctg Phe Arg Ala Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile Tyr Leu 420 425 430	1296
ggc ttc ggg cag gac ctg tca gct ggg agg ccc aag gag aag agc ctg Gly Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys Glu Lys Ser Leu 435 440 445	1344
gtc ctg gtg aag ctg gaa ccc tgg ctg tgc cga gtg cac cta gag ggc Val Leu Val Lys Leu Glu Pro Trp Leu Cys Arg Val His Leu Glu Gly 450 455 460	1392
acg cag cgt gag ggt gtg tct tcc ctg gat agc agc gac ctc gac ctc Thr Gln Arg Glu Gly Val Ser Ser Leu Asp Ser Ser Asp Leu Asp Leu 465 470 475 480	1440
tgc ctg tcc agc gcc aac agc ctc tat gac gac atc gag tgc ttc ctt Cys Leu Ser Ser Ala Asn Ser Leu Tyr Asp Asp Ile Glu Cys Phe Leu 485 490 495	1488
atg gag ctg gag cag ccc gcc tag Met Glu Leu Glu Gln Pro Ala 500	1512

&lt;210&gt; 9

&lt;211&gt; 503

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu 1 5 10 15
--

Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp 20 25 30
---

8/13

Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala  
35 40 45

Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala  
50 55 60

Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Pro Pro  
65 70 75 80

Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg  
85 90 95

Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser  
100 105 110

Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu  
115 120 125

Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro  
130 135 140

Ala Ala Val Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala  
145 150 155 160

His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala  
165 170 175

Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu  
180 185 190

Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr  
195 200 205

Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys  
210 215 220

Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val  
225 230 235 240

Glu Thr Thr Pro Ser Pro Gly Pro Gln Pro Ala Ala Leu Thr Thr Gly  
245 250 255

Glu Ala Ala Ala Pro Glu Ser Pro His Gln Ala Glu Pro Tyr Leu Ser  
260 265 270

Pro Ser Pro Ser Ala Cys Thr Ala Val Gln Glu Pro Ser Pro Gly Ala  
275 280 285

Leu Asp Val Thr Ile Met Tyr Lys Gly Arg Thr Val Leu Gln Lys Val  
290 295 300

Val Gly His Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp Pro Ala  
305 310 315 320

Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe Pro Ser Pro Ala Glu  
325 330 335

Leu Pro Asp Gln Lys Gln Leu Arg Tyr Thr Glu Glu Leu Leu Arg His  
340 345 350

Val Ala Pro Gly Leu His Leu Glu Leu Arg Gly Pro Gln Leu Trp Ala  
355 360 365

Arg Arg Met Gly Lys Cys Lys Val Tyr Trp Glu Val Gly Gly Pro Pro  
370 375 380

Gly Ser Ala Ser Pro Ser Thr Pro Ala Cys Leu Leu Pro Arg Asn Cys  
385 390 395 400

9/13

Asp Thr Pro Ile Phe Asp Phe Arg Val Phe Phe Gln Glu Leu Val Glu  
 405 410 415

Phe Arg Ala Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile Tyr Leu  
 420 425 430

Gly Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys Glu Lys Ser Leu  
 435 440 445

Val Leu Val Lys Leu Glu Pro Trp Leu Cys Arg Val His Leu Glu Gly  
 450 455 460

Thr Gln Arg Glu Gly Val Ser Ser Leu Asp Ser Ser Asp Leu Asp Leu  
 465 470 475 480

Cys Leu Ser Ser Ala Asn Ser Leu Tyr Asp Asp Ile Glu Cys Phe Leu  
 485 490 495

Met Glu Leu Glu Gln Pro Ala  
 500

&lt;210&gt; 10

&lt;211&gt; 1629

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1626)

&lt;400&gt; 10

atg gcc ttg gct cct gag agg gca gcc cca cgc gtg ctg ttc gga gag	48
Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu	
1 5 10 15	

tgg ctc ctt gga gag atc agc agc ggc tgc tat gag ggg ctg cag tgg	96
Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp	
20 25 30	

ctg gac gag gcc cgc acc tgt ttc cgc gtg ccc tgg aag cac ttc gcg	144
Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala	
35 40 45	

cgc aag gac ctg agc gag gcc gac gcg cgc atc ttc aag gcc tgg gct	192
Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala	
50 55 60	

gtg gcc cgc ggc agg tgg ccg cct agc agc agg gga ggt ggc ccg ccc	240
Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro	
65 70 75 80	

ccc gag gct gag act gcg gag cgc gcc ggc tgg aaa acc aac ttc cgc	288
Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg	
85 90 95	

tgc gca ctg cgc agc acg cgt cgc ttc gtg atg ctg cggt gat aac tcg	336
Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser	
100 105 110	

10/13

ggg gac ccg gcc gac ccg cac aag gtg tac gcg ctc agc cgg gag ctg Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu 115 120 125	384
tgc tgg cga gaa ggc cca ggc acg gac cag act gag gca gag gcc ccc Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro 130 135 140	432
gca gct gtc cca cca cca cag ggt ggg ccc cca ggg cca ttc ttg gca Ala Ala Val Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala 145 150 155 160	480
cac aca cat gct gga ctc caa gcc cca ggc ccc ctc cct gcc cca gct His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala 165 170 175	528
ggt gac aag ggg gac ctc ctc cag gca gtg caa cag agc tgc ctg Gly Asp Lys Gly Asp Leu Leu Gln Ala Val Gln Gln Ser Cys Leu 180 185 190	576
gca gac cat ctg ctg aca gcg tca tgg ggg gca gat cca gtc cca acc Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr 195 200 205	624
aag gct cct gga gag gga caa gaa ggg ctt ccc ctg act ggg gcc tgt Lys Ala Pro Gly Glu Gly Gln Glu Leu Pro Leu Thr Gly Ala Cys 210 215 220	672
gct gga ggc cca ggg ctc cct gct ggg gag ctg tac ggg tgg gca gta Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val 225 230 235 240	720
gag acg acc ccc agc ccc act tct gat acc cag gaa gac att ctg gat Glu Thr Thr Pro Ser Pro Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp 245 250 255	768
gag tta ctg ggt aac atg gtg ttg gcc cca ctc cca gat ccg gga ccc Glu Leu Leu Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro 260 265 270	816
cca agc ctg gct gta gcc cct gag ccc tgc cct cag ccc ctg cgg agc Pro Ser Leu Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser 275 280 285	864
ccc agc ttg gac aat ccc act ccc ttc cca aac ctg ggg ccc tct gag Pro Ser Leu Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu 290 295 300	912
aac cca ctg aag cgg ctg ttg gtg cgg ggg gaa gag tgg gag ttc gag Asn Pro Leu Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu 305 310 315 320	960
gtg aca gcc ttc tac cgg ggc cgc caa gtc ttc cag cag acc atc tcc Val Thr Ala Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser 325 330 335	1008
tgc ccg gag ggc ctg cgg ctg gtg ggg tcc gaa gtg gga gac agg acg Cys Pro Glu Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr 340 345 350	1056
ctg cct gga tgg cca gtc aca ctg cca gac cct ggc atg tcc ctg aca Leu Pro Gly Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr 355 360 365	1104
gac agg gga gtg atg agc tac gtg agg cat gtg ctg agc tgc ctg ggt Asp Arg Gly Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly 370 375 380	1152

11/13

ggg gga ctg gct ctc tgg cggtt ggc ggg cag tgg ctc tgg gcc cag cgg Gly Gly Leu Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg 385 390 395 400	1200
ctg ggg cac tgc cac aca tac tgg gca gtg agc gag gag ctg ctc ccc Leu Gly His Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Pro 405 410 415	1248
aac agc ggg cat ggg cct gat ggc gag gtc ccc aag gac aag gaa gga Asn Ser Gly His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly 420 425 430	1296
ggc gtg ttt gac ctg ggg ccc ttc att gta gat ctg att acc ttc acg Gly Val Phe Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr 435 440 445	1344
gaa gga agc gga cgc tca cca cgc tat gcc ctc tgg ttc tgt gtg ggg Glu Gly Ser Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly 450 455 460	1392
gag tca tgg ccc cag gac cag ccg tgg acc aag agg ctc gtg atg gtc Glu Ser Trp Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val 465 470 475 480	1440
aag gtt gtg ccc acg tgc ctc agg gcc ttg gta gaa atg gcc cgg gta Lys Val Val Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val 485 490 495	1488
ggg ggt gcc tcc tcc ctg gag aat act gtg gac ctg cac att gac aac Gly Gly Ala Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn 500 505 510	1536
gac cac cca ctc gac ctc gac gac cag tac aag gcc tac ctg cag Asp His Pro Leu Asp Leu Asp Asp Gln Tyr Lys Ala Tyr Leu Gln 515 520 525	1584
gac ttg gtg gag ggc atg gat ttc cag ggc cct ggg gag agc tga Asp Leu Val Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser 530 535 540	1629

&lt;210&gt; 11

&lt;211&gt; 542

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu  
 1 5 10 15

Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp  
 20 25 30

Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala  
 35 40 45

Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala  
 50 55 60

Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Pro Pro  
 65 70 75 80

Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg  
 85 90 95

12/13

Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser  
100 105 110

Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu  
115 120 125

Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro  
130 135 140

Ala Ala Val Pro Pro Gln Gly Pro Pro Gly Pro Phe Leu Ala  
145 150 155 160

His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala  
165 170 175

Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu  
180 185 190

Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr  
195 200 205

Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys  
210 215 220

Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val  
225 230 235 240

Glu Thr Thr Pro Ser Pro Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp  
245 250 255

Glu Leu Leu Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro  
260 265 270

Pro Ser Leu Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser  
275 280 285

Pro Ser Leu Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu  
290 295 300

Asn Pro Leu Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu  
305 310 315 320

Val Thr Ala Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser  
325 330 335

Cys Pro Glu Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr  
340 345 350

Leu Pro Gly Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr  
355 360 365

Asp Arg Gly Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly  
370 375 380

Gly Gly Leu Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg  
385 390 395 400

Leu Gly His Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro  
405 410 415

Asn Ser Gly His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly  
420 425 430

Gly Val Phe Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr  
435 440 445

Glu Gly Ser Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly  
450 455 460

13/13

Glu Ser Trp Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val  
465 470 475 480

Lys Val Val Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val  
485 490 495

Gly Gly Ala Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn  
500 505 510

Asp His Pro Leu Asp Leu Asp Asp Gln Tyr Lys Ala Tyr Leu Gln  
515 520 525

Asp Leu Val Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser  
530 535 540



10 Rec'd REC'D 24 MAY 2001 #  
09/647965 >

<110> Hiscott, John  
Lin, Rongtuan

<120> HIGHLY ACTIVE FORMS OF INTERFERON  
REGULATORY FACTOR PROTEINS

<130> A33606-PCT-USA 071235.0111

<140> US 09/647,965  
<141> 2000-10-06

<150> PCT/CA99/00314  
<151> 1999-04-07

<150> CA 2,234,588  
<151> 1998-04-07

<160> 11

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 1284  
<212> DNA  
<213> Homo sapiens

<220>  
<221> CDS  
<222> (1)...(1284)

<400> 1 48  
atg gga acc cca aag cca cg<sup>g</sup> atc ctg ccc tgg ctg gtg tcg cag ctg  
Met Gly Thr Pro Lys Pro Arg Ile Leu Pro Trp Leu Val Ser Gln Leu  
1 5 10 15

gac ctg ggg caa ctg gag ggc gtg gcc tgg gtg aac aag agc cgc acg 96  
Asp Leu Gly Gln Leu Glu Gly Val Ala Trp Val Asn Lys Ser Arg Thr  
20 25 30

cgc ttc cgc atc cct tgg aag cac ggc cta cgg cag gat gca cag cag 144  
Arg Phe Arg Ile Pro Trp Lys His Gly Leu Arg Gln Asp Ala Gln Gln  
35 40 45

gag gat ttc gga atc ttc cag gcc tgg gcc gag gcc act ggt gca tat 192  
Glu Asp Phe Gly Ile Phe Gln Ala Trp Ala Glu Ala Thr Gly Ala Tyr  
50 55 60

gtt ccc ggg agg gat aag cca gac ctg cca acc tgg aag agg aat ttc 240  
Val Pro Gly Arg Asp Lys Pro Asp Leu Pro Thr Trp Lys Arg Asn Phe  
65 70 75 80

cgc tct gcc ctc aac cgc aaa gaa ggg ttg cgt tta gca gag gac cgg 288  
Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu Arg Leu Ala Glu Asp Arg  
85 90 95

agc aag gac cct cac gac cca cat aaa atc tac gag ttt gtg aac tca Ser Lys Asp Pro His Asp Pro His Lys Ile Tyr Glu Phe Val Asn Ser	336
100 105 110	
gga gtt ggg gac ttt tcc cag cca gac acc tct ccg gac acc aat ggt Gly Val Gly Asp Phe Ser Gln Pro Asp Thr Ser Pro Asp Thr Asn Gly	384
115 120 125	
gga ggc agt act tct gat acc cag gaa gac att ctg gat gag tta ctg Gly Gly Ser Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu	432
130 135 140	
ggt aac atg gtg ttg gcc cca ctc cca gat ccg gga ccc cca agc ctg Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu	480
145 150 155 160	
gct gta gcc cct gag ccc tgc cct cag ccc ctg cgg agc ccc agc ttg Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser Pro Ser Leu	528
165 170 175	
gac aat ccc act ccc ttc cca aac ctg ggg ccc tct gag aac cca ctg Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn Pro Leu	576
180 185 190	
aag cgg ctg ttg gtg ccg ggg gaa gag tgg gag ttc gag gtg aca gcc Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu Val Thr Ala	624
195 200 205	
ttc tac cgg ggc cgc caa gtc ttc cag cag acc atc tcc tgc ccg gag Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser Cys Pro Glu	672
210 215 220	
ggc ctg cgg ctg gtg ggg tcc gaa gtg gga gac agg acg ctg cct gga Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr Leu Pro Gly	720
225 230 235 240	
tgg cca gtc aca ctg cca gac cct ggc atg tcc ctg aca gac agg gga Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr Asp Arg Gly	768
245 250 255	
gtg atg agc tac gtg agg cat gtg ctg agc tgc ctg ggt ggg gga ctg Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly Gly Leu	816
260 265 270	
gct ctc tgg cgg gcc ggg cag tgg ctc tgg gcc cag cgg ctg ggg cac Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg Leu Gly His	864
275 280 285	
tgc cac aca tac tgg gca gtg agc gag gag ctg ctc ccc aac agc ggg Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro Asn Ser Gly	912
290 295 300	
cat ggg cct gat ggc gag gtc ccc aag gac aag gaa gga ggc gtg ttt His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly Gly Val Phe	960
305 310 315 320	
gac ctg ggg ccc ttc att gta gat ctg att acc ttc acg gaa gga agc	1008

Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr Glu Gly Ser			
325	330	335	
gga cgc tca cca cgc tat gcc ctc tgg ttc tgt gtg ggg gag tca tgg			1056
Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly Glu Ser Trp			
340	345	350	
ccc cag gac cag ccg tgg acc aag agg ctc gtg atg gtc aag gtt gtg			1104
Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val Lys Val Val			
355	360	365	
ccc acg tgc ctc agg gcc ttg gta gaa atg gcc cggt gta ggg ggt gcc			1152
Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val Gly Gly Ala			
370	375	380	
tcc tcc ctg gag aat act gtg gac ctg cac att gac aac gac cac cca			1200
Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn Asp His Pro			
385	390	395	400
ctc gac ctc gac gac cag tac aag gcc tac ctg cag gac ttg gtg			1248
Leu Asp Leu Asp Asp Gln Tyr Lys Ala Tyr Leu Gln Asp Leu Val			
405	410	415	
gag ggc atg gat ttc cag ggc cct ggg gag agc tga			1284
Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser *			
420	425		

<210> 2  
<211> 427  
<212> PRT  
<213> Homo sapiens

<400> 2			
Met Gly Thr Pro Lys Pro Arg Ile Leu Pro Trp Leu Val Ser Gln Leu			
1	5	10	15
Asp Leu Gly Gln Leu Glu Gly Val Ala Trp Val Asn Lys Ser Arg Thr			
20	25	30	
Arg Phe Arg Ile Pro Trp Lys His Gly Leu Arg Gln Asp Ala Gln Gln			
35	40	45	
Glu Asp Phe Gly Ile Phe Gln Ala Trp Ala Glu Ala Thr Gly Ala Tyr			
50	55	60	
Val Pro Gly Arg Asp Lys Pro Asp Leu Pro Thr Trp Lys Arg Asn Phe			
65	70	75	80
Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu Arg Leu Ala Glu Asp Arg			
85	90	95	
Ser Lys Asp Pro His Asp Pro His Lys Ile Tyr Glu Phe Val Asn Ser			
100	105	110	
Gly Val Gly Asp Phe Ser Gln Pro Asp Thr Ser Pro Asp Thr Asn Gly			
115	120	125	
Gly Gly Ser Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu			
130	135	140	
Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu			
145	150	155	160
Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser Pro Ser Leu			
165	170	175	
Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn Pro Leu			

180	185	190													
Lys	Arg	Leu	Leu	Val	Pro	Gly	Glu	Glu	Trp	Glu	Phe	Glu	Val	Thr	Ala
195							200				205				
Phe	Tyr	Arg	Gly	Arg	Gln	Val	Phe	Gln	Gln	Thr	Ile	Ser	Cys	Pro	Glu
210						215				220					
Gly	Leu	Arg	Leu	Val	Gly	Ser	Glu	Val	Gly	Asp	Arg	Thr	Leu	Pro	Gly
225					230				235				240		
Trp	Pro	Val	Thr	Leu	Pro	Asp	Pro	Gly	Met	Ser	Leu	Thr	Asp	Arg	Gly
					245			250				255			
Val	Met	Ser	Tyr	Val	Arg	His	Val	Leu	Ser	Cys	Leu	Gly	Gly	Gly	Leu
					260			265				270			
Ala	Leu	Trp	Arg	Ala	Gly	Gln	Trp	Leu	Trp	Ala	Gln	Arg	Leu	Gly	His
					275			280			285				
Cys	His	Thr	Tyr	Trp	Ala	Val	Ser	Glu	Glu	Leu	Leu	Pro	Asn	Ser	Gly
					290			295			300				
His	Gly	Pro	Asp	Gly	Glu	Val	Pro	Lys	Asp	Lys	Glu	Gly	Gly	Val	Phe
305					310				315				320		
Asp	Leu	Gly	Pro	Phe	Ile	Val	Asp	Leu	Ile	Thr	Phe	Thr	Glu	Gly	Ser
					325				330			335			
Gly	Arg	Ser	Pro	Arg	Tyr	Ala	Leu	Trp	Phe	Cys	Val	Gly	Glu	Ser	Trp
					340				345			350			
Pro	Gln	Asp	Gln	Pro	Trp	Thr	Lys	Arg	Leu	Val	Met	Val	Lys	Val	Val
					355				360			365			
Pro	Thr	Cys	Leu	Arg	Ala	Leu	Val	Glu	Met	Ala	Arg	Val	Gly	Gly	Ala
					370				375			380			
Ser	Ser	Leu	Glu	Asn	Thr	Val	Asp	Leu	His	Ile	Asp	Asn	Asp	His	Pro
385						390				395			400		
Leu	Asp	Leu	Asp	Asp	Asp	Gln	Tyr	Lys	Ala	Tyr	Leu	Gln	Asp	Leu	Val
						405				410			415		
Glu	Gly	Met	Asp	Phe	Gln	Gly	Pro	Gly	Glu	Ser					
					420				425						

<210> 3  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 3  
Ile Ser Asn Ser His Pro Leu Ser Leu Thr Ser Asp Gln  
1               5               10

<210> 4  
<211> 4  
<212> PRT  
<213> Homo sapiens

<400> 4  
Gly Ala Ala Ala  
1

<210> 5  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 5		
Gly Ala Ala Ala Asn Asn		
1	5	
<210> 6		
<211> 15		
<212> DNA		
<213> Homo sapiens		
<400> 6		
ggaaaactga aaggg		15
<210> 7		
<211> 30		
<212> DNA		
<213> Homo sapiens		
<400> 7		
gatcggggaaa gggaaaccga aactgaagcc		30
<210> 8		
<211> 1512		
<212> DNA		
<213> Homo sapiens		
<220>		
<221> CDS		
<222> (1)...(1512)		
<400> 8		
atg gcc ttg gct cct gag agg gca gcc cca cgc gtg ctg ttc gga gag		48
Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu		
1                         5                         10                         15		
tgg ctc ctt gga gag atc agc agc ggc tgc tat gag ggg ctg cag tgg		96
Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp		
20                         25                         30		
ctg gac gag gcc cgc acc tgt ttc cgc gtg ccc tgg aag cac ttc gcg		144
Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala		
35                         40                         45		
cgc aag gac ctg agc gag gcc gac gcg cgc atc ttc aag gcc tgg gct		192
Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala		
50                         55                         60		
gtg gcc cgc ggc agg tgg ccg cct agc agc agg gga ggt ggc ccc		240
Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Pro Pro		
65                         70                         75                         80		
ccc gag gct gag act gcg gag cgc gcc ggc tgg aaa acc aac ttc cgc		288
Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg		
85                         90                         95		
tgc gca ctg cgc agc acg cgt cgc ttc gtg atg ctg cgg gat aac tcg		336

Cys	Ala	Leu	Arg	Ser	Thr	Arg	Arg	Phe	Val	Met	Leu	Arg	Asp	Asn	Ser	
																100
																105
																110
ggg	gac	ccg	gcc	gac	ccg	cac	aag	gtg	tac	gcg	ctc	agc	cg	gag	ctg	384
Gly	Asp	Pro	Ala	Asp	Pro	His	Lys	Val	Tyr	Ala	Leu	Ser	Arg	Glu	Leu	
																115
																120
																125
tgc	tgg	cga	gaa	ggc	cca	ggc	acg	gac	cag	act	gag	gca	gag	gcc	ccc	432
Cys	Trp	Arg	Glu	Gly	Pro	Gly	Thr	Asp	Gln	Thr	Glu	Ala	Glu	Ala	Pro	
																130
																135
																140
gca	gct	gtc	cca	cca	cca	cag	gg	gg	ccc	cca	gg	cca	ttc	ttg	gca	480
Ala	Ala	Ala	Val	Pro	Pro	Pro	Gln	Gly	Gly	Pro	Pro	Gly	Pro	Phe	Leu	
																145
																150
																155
																160
cac	aca	cat	gct	gga	ctc	caa	gcc	cca	ggc	ccc	ctc	cct	gcc	cca	gct	528
His	Thr	His	Ala	Gly	Leu	Gln	Ala	Pro	Gly	Pro	Leu	Pro	Ala	Pro	Ala	
																165
																170
																175
gg	gac	aag	gg	gac	ctc	ctg	ctc	cag	gca	gt	caa	cag	agc	tgc	ctg	576
Gly	Asp	Lys	Gly	Asp	Leu	Leu	Leu	Gln	Ala	Val	Gln	Gln	Ser	Cys	Leu	
																180
																185
																190
gca	gac	cat	ctg	ctg	aca	g	tca	tgg	gg	gca	gat	cca	gtc	cca	acc	624
Ala	Asp	His	Leu	Leu	Thr	Ala	Ser	Trp	Gly	Ala	Asp	Pro	Val	Pro	Thr	
																195
																200
																205
aag	gct	cct	gga	gag	gga	caa	gaa	gg	ctt	ccc	ctg	act	gg	gg	tgt	672
Lys	Ala	Pro	Gly	Glu	Gly	Gln	Gly	Glu	Gly	Leu	Pro	Leu	Thr	Gly	Ala	
																210
																215
																220
gct	gga	ggc	cca	ggg	ctc	cct	gct	ggg	gag	ctg	tac	ggg	tgg	gca	gta	720
Ala	Gly	Gly	Pro	Gly	Leu	Pro	Ala	Gly	Glu	Leu	Tyr	Gly	Trp	Ala	Val	
																225
																230
																235
gag	gcc	g	cc	gg	cc	cc	cag	cc	g	cc	g	ca	cta	ac	ac	768
Glu	Thr	Thr	Pro	Ser	Pro	Gly	Pro	Gln	Pro	Ala	Ala	Leu	Thr	Thr	Gly	
																245
																250
																255
gag	gcc	g	cc	gg	cc	cc	cag	cc	g	cc	g	ca	tg	tc	tca	816
Glu	Ala	Ala	Ala	Pro	Glu	Ser	Pro	His	Gln	Ala	Glu	Pro	Tyr	Leu	Ser	
																260
																265
																270
ccc	tcc	cca	agc	ccc	gg	cc	cag	cc	g	cc	ag	cc	gg	gg	g	864
Pro	Ser	Pro	Ser	Ala	Cys	Thr	Ala	Val	Gln	Glu	Pro	Ser	Pro	Gly	Ala	
																275
																280
																285
ctg	gac	gt	acc	atc	atg	tac	aag	gg	cgc	ac	gt	ctg	cag	aag	gt	912
Leu	Asp	Val	Thr	Ile	Met	Tyr	Lys	Gly	Arg	Thr	Val	Leu	Gln	Lys	Val	
																290
																295
																300
gt	g	ga	c	cc	ag	tc	ac	tt	ct	ta	tc	gg	cc	ca	gc	960
Val	Gly	His	Pro	Ser	Cys	Thr	Phe	Leu	Tyr	Gly	Pro	Pro	Asp	Pro	Ala	
																305
																310
																315
																320
gtc	cg	g	cc	ac	g	cc	cag	cag	g	ta	tt	cc	ag	cc	gg	1008
Val	Arg	Ala	Thr	Asp	Pro	Gln	Gln	Val	Ala	Phe	Pro	Ser	Pro	Ala	Glu	

325	330	335	
ctc ccg gac cag aag cag ctg cgc tac acg gag gaa ctg ctg cgg cac Leu Pro Asp Gln Lys Gln Leu Arg Tyr Thr Glu Glu Leu Leu Arg His 340	345	350	1056
gtg gcc cct ggg ttg cac ctg gag ctt cgg ggg cca cag ctg tgg gcc Val Ala Pro Gly Leu His Leu Glu Leu Arg Gly Pro Gln Leu Trp Ala 355	360	365	1104
cg <sup>g</sup> cgc atg ggc aag tgc aag gtg tac tgg gag gtg ggc gga ccc cca Arg Arg Met Gly Lys Cys Lys Val Tyr Trp Glu Val Gly Gly Pro Pro 370	375	380	1152
ggc tcc gcc agc ccc tcc acc cca gcc tgc ctg ctg cct cgg aac tgt Gly Ser Ala Ser Pro Ser Thr Pro Ala Cys Leu Leu Pro Arg Asn Cys 385	390	395	1200
gac acc ccc atc ttc gac ttc aga gtc ttc ttc caa gag ctg gtg gaa Asp Thr Pro Ile Phe Asp Phe Arg Val Phe Phe Gln Glu Leu Val Glu 405	410	415	1248
ttc cgg gca cgg cag cgc cgt ggc tcc cca cgc tat acc atc tac ctg Phe Arg Ala Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile Tyr Leu 420	425	430	1296
ggc ttc ggg cag gac ctg tca gct ggg agg ccc aag gag aag agc ctg Gly Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys Glu Lys Ser Leu 435	440	445	1344
gtc ctg gtg aag ctg gaa ccc tgg ctg tgc cga gtg cac cta gag ggc Val Leu Val Lys Leu Glu Pro Trp Leu Cys Arg Val His Leu Glu Gly 450	455	460	1392
acg cag cgt gag ggt gtg tct tcc ctg gat agc agc gac ctc gac ctc Thr Gln Arg Glu Gly Val Ser Ser Leu Asp Ser Ser Asp Leu Asp Leu 465	470	475	1440
tgc ctg tcc agc gcc aac agc ctc tat gac gac atc gag tgc ttc ctt Cys Leu Ser Ser Ala Asn Ser Leu Tyr Asp Asp Ile Glu Cys Phe Leu 485	490	495	1488
atg gag ctg gag cag ccc gcc tag Met Glu Leu Glu Gln Pro Ala *	500		1512

<210> 9  
<211> 503  
<212> PRT  
<213> Homo sapiens

<400> 9  
Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu  
1 5 10 15  
Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp  
20 25 30

Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala  
35 40 45  
Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala  
50 55 60  
Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro  
65 70 75 80  
Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg  
85 90 95  
Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser  
100 105 110  
Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu  
115 120 125  
Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro  
130 135 140  
Ala Ala Val Pro Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala  
145 150 155 160  
His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala  
165 170 175  
Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu  
180 185 190  
Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr  
195 200 205  
Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys  
210 215 220  
Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val  
225 230 235 240  
Glu Thr Thr Pro Ser Pro Gly Pro Gln Pro Ala Ala Leu Thr Thr Gly  
245 250 255  
Glu Ala Ala Ala Pro Glu Ser Pro His Gln Ala Glu Pro Tyr Leu Ser  
260 265 270  
Pro Ser Pro Ser Ala Cys Thr Ala Val Gln Glu Pro Ser Pro Gly Ala  
275 280 285  
Leu Asp Val Thr Ile Met Tyr Lys Gly Arg Thr Val Leu Gln Lys Val  
290 295 300  
Val Gly His Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp Pro Ala  
305 310 315 320  
Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe Pro Ser Pro Ala Glu  
325 330 335  
Leu Pro Asp Gln Lys Gln Leu Arg Tyr Thr Glu Glu Leu Leu Arg His  
340 345 350  
Val Ala Pro Gly Leu His Leu Glu Leu Arg Gly Pro Gln Leu Trp Ala  
355 360 365  
Arg Arg Met Gly Lys Cys Lys Val Tyr Trp Glu Val Gly Gly Pro Pro  
370 375 380  
Gly Ser Ala Ser Pro Ser Thr Pro Ala Cys Leu Leu Pro Arg Asn Cys  
385 390 395 400  
Asp Thr Pro Ile Phe Asp Phe Arg Val Phe Phe Gln Glu Leu Val Glu  
405 410 415  
Phe Arg Ala Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile Tyr Leu  
420 425 430  
Gly Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys Glu Lys Ser Leu  
435 440 445  
Val Leu Val Lys Leu Glu Pro Trp Leu Cys Arg Val His Leu Glu Gly  
450 455 460  
Thr Gln Arg Glu Gly Val Ser Ser Leu Asp Ser Ser Asp Leu Asp Leu  
465 470 475 480  
Cys Leu Ser Ser Ala Asn Ser Leu Tyr Asp Asp Ile Glu Cys Phe Leu



165	170	175	
ggt gac aag ggg gac ctc ctg ctc cag gca gtg caa cag cag agc tgc ctg Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu 180	185	190	576
gca gac cat ctg ctg aca gcg tca tgg ggg gca gat cca gtc cca acc Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr 195	200	205	624
aag gct cct gga gag gga caa gaa ggg ctt ccc ctg act ggg gcc tgt Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys 210	215	220	672
gct gga ggc cca ggg ctc cct gct ggg gag ctg tac ggg tgg gca gta Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val 225	230	235	720
gag acg acc ccc agc ccc act tct gat acc cag gaa gac att ctg gat Glu Thr Thr Pro Ser Pro Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp 245	250	255	768
gag tta ctg ggt aac atg gtg ttg gcc cca ctc cca gat ccg gga ccc Glu Leu Leu Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro 260	265	270	816
cca agc ctg gct gta gcc cct gag ccc tgc cct cag ccc ctg cgg agc Pro Ser Leu Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser 275	280	285	864
ccc agc ttg gac aat ccc act ccc ttc cca aac ctg ggg ccc tct gag Pro Ser Leu Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu 290	295	300	912
aac cca ctg aag cgg ctg ttg gtg ccg ggg gaa gag tgg gag ttc gag Asn Pro Leu Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu 305	310	315	960
gtg aca gcc ttc tac cgg ggc cgc caa gtc ttc cag cag acc atc tcc Val Thr Ala Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser 325	330	335	1008
tgc ccg gag ggc ctg cgg ctg gtg ggg tcc gaa gtg gga gac agg acg Cys Pro Glu Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr 340	345	350	1056
ctg cct gga tgg cca gtc aca ctg cca gac cct ggc atg tcc ctg aca Leu Pro Gly Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr 355	360	365	1104
gac agg gga gtg atg agc tac gtg agg cat gtg ctg agc tgc ctg ggt Asp Arg Gly Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly 370	375	380	1152
ggg gga ctg gct ctc tgg cgg gcc ggg cag tgg ctc tgg gcc cag cgg Gly Gly Leu Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg 385	390	395	1200
			400

ctg ggg cac tgc cac aca tac tgg gca gtg agc gag gag ctg ctc ccc Leu Gly His Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro	405	410	415	1248	
aac agc ggg cat ggg cct gat ggc gag gtc ccc aag gac aag gaa gga Asn Ser Gly His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly	420	425	430	1296	
ggc gtg ttt gac ctg ggg ccc ttc att gta gat ctg att acc ttc acg Gly Val Phe Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr	435	440	445	1344	
gaa gga agc gga cgc tca cca cgc tat gcc ctc tgg ttc tgt gtg ggg Glu Gly Ser Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly	450	455	460	1392	
gag tca tgg ccc cag gac cag ccg tgg acc aag agg ctc gtg atg gtc Glu Ser Trp Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val	465	470	475	480	1440
aag gtt gtg ccc acg tgc ctc agg gcc ttg gta gaa atg gcc cggt gta Lys Val Val Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val	485	490	495	1488	
ggg ggt gcc tcc tcc ctg gag aat act gtg gac ctg cac att gac aac Gly Gly Ala Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn	500	505	510	1536	
gac cac cca ctc gac gac gac cag tac aag gcc tac ctg cag Asp His Pro Leu Asp Leu Asp Asp Gln Tyr Lys Ala Tyr Leu Gln	515	520	525	1584	
gac ttg gtg gag ggc atg gat ttc cag ggc cct ggg gag agc tga Asp Leu Val Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser *	530	535	540	1629	

<210> 11  
<211> 542  
<212> PRT  
<213> Homo sapiens

<400> 11  
Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu  
1               5               10               15  
Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp  
20               25               30  
Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala  
35               40               45  
Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala  
50               55               60  
Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Pro Pro  
65               70               75               80  
Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg  
85               90               95

Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser  
100 105 110  
Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu  
115 120 125  
Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro  
130 135 140  
Ala Ala Val Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala  
145 150 155 160  
His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala  
165 170 175  
Gly Asp Lys Gly Asp Leu Leu Gln Ala Val Gln Gln Ser Cys Leu  
180 185 190  
Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr  
195 200 205  
Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys  
210 215 220  
Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val  
225 230 235 240  
Glu Thr Thr Pro Ser Pro Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp  
245 250 255  
Glu Leu Leu Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro  
260 265 270  
Pro Ser Leu Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser  
275 280 285  
Pro Ser Leu Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu  
290 295 300  
Asn Pro Leu Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu  
305 310 315 320  
Val Thr Ala Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser  
325 330 335  
Cys Pro Glu Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr  
340 345 350  
Leu Pro Gly Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr  
355 360 365  
Asp Arg Gly Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly  
370 375 380  
Gly Gly Leu Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg  
385 390 395 400  
Leu Gly His Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro  
405 410 415  
Asn Ser Gly His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly  
420 425 430  
Gly Val Phe Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr  
435 440 445  
Glu Gly Ser Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly  
450 455 460  
Glu Ser Trp Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val  
465 470 475 480  
Lys Val Val Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val  
485 490 495  
Gly Gly Ala Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn  
500 505 510  
Asp His Pro Leu Asp Leu Asp Asp Asp Gln Tyr Lys Ala Tyr Leu Gln  
515 520 525  
Asp Leu Val Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser  
530 535 540

PART 34 ANDT

42 100-000-00

## CLAIMS:

1. A modified interferon regulatory factor (IRF) protein, the protein comprising at least one modified serine or threonine phosphoacceptor site in the carboxy-terminus domain, with the proviso that where said IRF protein is IRF-3, said at least one modified phosphoacceptor site does not comprise Ser-385 or Ser-386.
2. The interferon regulatory factor (IRF) protein according to claim 1, wherein cytokine gene activation by the modified IRF is increased relative to cytokine gene activation by a corresponding wild type IRF protein.
3. The interferon regulatory factor (IRF) protein according to claim 1 or 2, wherein the modified IRF is an IRF-3 protein modified at at least one serine or threonine phosphoacceptor site.
4. The interferon regulatory factor (IRF) protein according to claim 1 or 2, wherein the modified IRF is an IRF-7 protein modified at at least one serine or threonine phosphoacceptor site.
5. The interferon regulatory factor (IRF) protein according to any one of claims 1 to 4, wherein the at least one modified phosphoacceptor site is modified by phosphorylation.

43 05.00 CA

6. The interferon regulatory factor (IRF) protein according to any one of claims 1 to 4, wherein the at least one modified phosphoacceptor site comprises an amino acid residue having an acidic side chain.

5

7. The interferon regulatory factor (IRF) protein according to claim 6, wherein the amino acid residue is aspartic acid.

8. The interferon regulatory factor (IRF) protein according to claim 5, wherein the modified IRF is IRF-3 modified at a site selected from at least one of Ser-396, Ser-398, Ser-402, Thr-404 and Ser-405.

9. The interferon regulatory factor (IRF) protein according to claim 8, wherein the modified IRF is IRF-3 modified at Ser-396, Ser-398, Ser-402, Thr-404 and Ser-405 sites

20 10. The interferon regulatory factor (IRF) protein according to claim 9, wherein the modified IRF comprises a carboxy-terminus domain of Ser-396, Ser-398, Ser-402, Thr-404 and Ser-405 and an amino-terminus domain from IRF-7.

25 11. The interferon regulatory factor (IRF) protein  
according to claim 6 or 7, wherein the modified IRF is IRF-3

05-06-2000

ART 34 ANDT

44

modified at a site selected from at least one of Ser-396, Ser-398, Ser-402, Thr-404 and Ser-405.

12. The interferon regulatory factor (IRF) protein

5 according to claim 11, wherein the modified IRF is IRF-3

modified at Ser-396, Ser-398, Ser-402, Thr-404 and Ser-405

sites.

13. The interferon regulatory factor (IRF) protein

0 according to claim 12 having SEQ ID NO. 2 (IRF-3 (5D)).

14. The interferon regulatory factor (IRF) protein

according to claim 12, wherein the modified IRF comprises a

carboxy-terminus domain of Ser-396, Ser-398, Ser-402, Thr-404

25 and Ser-405 and an amino-terminus domain from IRF-7.

15. The interferon regulatory factor (IRF) protein

according to claim 14, wherein the modified IRF has an amino-

terminal domain comprising residues 1 to 246 of IRF-7 and a

20 carboxy-terminal domain comprising residues 132 to 427 of IRF-3

modified by replacement each of Ser-396, Ser-398, Ser-402, Thr-

404 and Ser-405 by an aspartic acid residue.

16. The interferon regulatory factor (IRF) protein

25 according to claim 15 having SEQ ID NO. 11 (IRF-7(1-246)/IRF-

→ 3 (5D) (132-427)).

ART 34 AMDT

45.000.000.00

17. The interferon regulatory factor (IRF) protein according to claim 5, wherein the modified IRF is IRF-7 modified at a site selected from at least one of Ser-477 and Ser-479.

5

18. The interferon regulatory factor (IRF) protein according to claim 17, wherein the modified IRF-7 is modified at Ser-477 and Ser-479 sites.

TOP SECRET//SI//FOUO

10 19. The interferon regulatory factor (IRF) protein according to claims 6 or 7, wherein the modified IRF is IRF-7 modified at a site selected from at least one of Ser-477 and Ser-479.

15 20. The interferon regulatory factor (IRF) protein according to claim 19, wherein the modified IRF-7 is modified at Ser-477 and Ser-479 sites.

21. The interferon regulatory factor (IRF) protein  
20 according to claim 20 having SEQ ID NO. 9 (IRF-7(2D)).

22. A nucleotide sequence selected from:  
23 (a) a first nucleotide sequence which encodes  
24 the interferon regulatory factor (IRF) protein according to any  
25 one of claims 6, 7, 11 to 16, 19, 20 or 21, or

ART 34 AMENDT

46

(b) a second nucleotide sequence that is hybridizable under stringent conditions with the complement of the first nucleotide sequence, wherein said second nucleotide sequence encodes an IRF protein wherein at least one serine or 5 threonine phosphoacceptor site comprises an amino acid residue having an acidic side chain.

23. The nucleotide sequence according to claim 22, having SEQ ID NO. 1.

10 24. The nucleotide sequence according to claim 22, having SEQ ID NO. 8.

15 25. The nucleotide sequence according to claim 22, having SEQ ID NO. 10.

26. A pharmaceutical composition comprising an effective amount of the interferon regulatory factor (IRF) protein according to any one of claims 1 to 21, together with a 20 pharmaceutically acceptable carrier, for the treatment of a viral infection.

27. The pharmaceutical composition according to claim 26, wherein the viral infection is selected from an influenza 25 infection, a herpes infection, a hepatitis infection and an HIV infection.

28. Use of the interferon regulatory factor (IRF) protein according to any one of claims 1 to 21 to activate a cytokine 30 gene.

ART 34 AMDT

47 103-06.00

29. The use according to claim 28, wherein the cytokine gene is an interferon gene or a chemokine gene.

30. Use of the interferon regulatory factor (IRF) protein  
5 according to any one of claims 1 to 21 in cancer treatment.

31. Use of the nucleotide sequence according to any one  
of claims 22 to 25 to modify a target cell of an organism.

10 32. A commercial package containing as an active pharmaceutical ingredient the pharmaceutical composition according to claim 26 together with instructions for its use for the treatment of a viral infection.

15 33. The commercial package according to claim 32, wherein the viral infection is selected from an influenza infection, a herpes infection, a hepatitis infection and an HIV infection.

34. A commercial package containing as an active  
20 pharmaceutical ingredient the interferon regulatory factor (IRF) protein according to any one of claims 1 to 21 together with instructions for its use for the treatment of cancer.

ART 34 AMDT

2/13

	cgc tct gcc ctc aac cgc aaa gaa ggg ttg cgt tta gca gag gac cgg Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu Arg Leu Ala Glu Asp Arg 85 90 95	288
	agc aag gac cct cac gac cca cat aaa atc tac gag ttt gtg aac tca Ser Lys Asp Pro His Asp Pro His Lys Ile Tyr Glu Phe Val Asn Ser 100 105 110	336
10	gga gtt ggg gac ttt tcc cag cca gac acc tct ccg gac acc aat ggt Gly Val Gly Asp Phe Ser Gln Pro Asp Thr Ser Pro Asp Thr Asn Gly 115 120 125	384
	gga ggc agt act tct gat acc cag gaa gac att ctg gat gag tta ctg Gly Gly Ser Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu 130 135 140	432
20	ggg aac atg gtg ttg gcc cca ctc cca gat ccg gga ccc cca agc ctg Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu 145 150 155 160	480
	gct gta gcc cct gag ccc tgc cct cag ccc ctg ccg agc ccc agc ttg Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser Pro Ser Leu 165 170 175	528
	gac aat ccc act ccc ttc cca aac ctg ggg ccc tct gag aac cca ctg Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn Pro Leu 180 185 190	576
30	aag cgg ctg ttg gtg ccc ggg gaa gag tgg gag ttc gag gtg aca gcc Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu Val Thr Ala 195 200 205	624
	tcc tac cgg ggc cgc caa gtc ttc cag cag acc atc tcc tgc ccg gag Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser Cys Pro Glu 210 215 220	672
40	ggc ctg cgg ctg gtg ggg tcc gaa gtg gga gac agg acg ctg cct gga Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr Leu Pro Gly 225 230 235 240	720
	tgg cca gtc aca ctg cca gac cct ggc atg tcc ctg aca gac agg gga Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr Asp Arg Gly 245 250 255	768
	gtg atg agc tac gtg agg cat gtg ctg agc tgc ctg ggt ggg gga ctg Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly Gly Leu 260 265 270	816
50	gct ctc tgg cgg gcc ggg cag tgg ctc tgg gcc cag cgg ctg ggg cac Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg Leu Gly His 275 280 285	864
	tgc cac aca tac tgg gca gtg agc gag gag ctg ctc ccc aac agc ggg Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro Asn Ser Gly 290 295 300	912
	cat ggg cct gat ggc gag gtc ccc aag gac aag gaa gga ggc gtg ttt His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly Gly Val Phe 305 310 315 320	960
60	gac ctg ggg ccc ttc att gta gat ctg att acc ttc acg gaa gga agc Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr Glu Gly Ser 325 330 335	1008
	gga cgc tca cca cgc tat gcc ctc tgg ttc tgt gtg ggg gag tca tgg Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly Glu Ser Trp 340 345 350	1056

3/13

M 08.08.01

AMENDED SHEET

ccc cag gac cag ccg tgg acc aag agg ctc gtg atg gtc aag gtt gtg Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val Lys Val Val 355 360 365	1104
ccc acg tgc ctc agg gcc ttg gta gaa atg gcc ccg gta ggg ggt gcc Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val Gly Gly Ala 370 375 380	1152
10 tcc tcc ctg gag aat act gtg gac ctg cac att gac aac gac cac cca Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn Asp His Pro 385 390 395 400	1200
ctc gac ctc gac gac cag tac aag gcc tac ctg cag gac ttg gtg Leu Asp Leu Asp Asp Asp Gln Tyr Lys Ala Tyr Leu Gln Asp Leu Val 405 410 415	1248
gag ggc atg gat ttc cag ggc cct ggg gag agc tga Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser 420 425	1284
20 <210> 2	
<211> 427	
<212> PRT	
<213> Homo sapiens	
<400> 2	
Met Gly Thr Pro Lys Pro Arg Ile Leu Pro Trp Leu Val Ser Gln Leu 1 5 10 15	
Asp Leu Gly Gln Leu Glu Gly Val Ala Trp Val Asn Lys Ser Arg Thr 30 20 25 30	
Arg Phe Arg Ile Pro Trp Lys His Gly Leu Arg Gln Asp Ala Gln Gln 35 40 45	
Glu Asp Phe Gly Ile Phe Gln Ala Trp Ala Glu Ala Thr Gly Ala Tyr 50 55 60	
Val Pro Gly Arg Asp Lys Pro Asp Leu Pro Thr Trp Lys Arg Asn Phe 65 70 75 80	
40 Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu Arg Leu Ala Glu Asp Arg 85 90 95	
Ser Lys Asp Pro His Asp Pro His Lys Ile Tyr Glu Phe Val Asn Ser 100 105 110	
Gly Val Gly Asp Phe Ser Gln Pro Asp Thr Ser Pro Asp Thr Asn Gly 115 120 125	
50 Gly Gly Ser Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu 130 135 140	
Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu 145 150 155 160	
Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser Pro Ser Leu 165 170 175	
60 Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn Pro Leu 180 185 190	

2/13

ART 34 AMDT  
Lys Arg

Lys	Arg	Leu	Leu	Val	Pro	Gly	Glu	Glu	Trp	Glu	Phe	Glu	Val	Thr	Ala	
195							200				205					
Phe	Tyr	Arg	Gly	Arg	Gln	Val	Phe	Gln	Gln	Thr	Ile	Ser	Cys	Pro	Glu	
210							215				220					
Gly	Leu	Arg	Leu	Val	Gly	Ser	Glu	Val	Gly	Asp	Arg	Thr	Leu	Pro	Gly	
225					230				235						240	
10	Trp	Pro	Val	Thr	Leu	Pro	Asp	Pro	Gly	Met	Ser	Leu	Thr	Asp	Arg	Gly
							245			250					255	
Val	Met	Ser	Tyr	Val	Arg	His	Val	Leu	Ser	Cys	Leu	Gly	Gly	Gly	Leu	
							260		265			270				
Ala	Leu	Trp	Arg	Ala	Gly	Gln	Trp	Leu	Trp	Ala	Gln	Arg	Leu	Gly	His	
				275				280			285					
20	Cys	His	Thr	Tyr	Trp	Ala	Val	Ser	Glu	Glu	Leu	Leu	Pro	Asn	Ser	Gly
							290	295			300					
His	Gly	Pro	Asp	Gly	Glu	Val	Pro	Lys	Asp	Lys	Glu	Gly	Gly	Val	Pha	
							305	310		315					320	
Asp	Leu	Gly	Pro	Phe	Ile	Val	Asp	Leu	Ile	Thr	Phe	Thr	Glu	Gly	Ser	
							325		330			335				
30	Gly	Arg	Ser	Pro	Arg	Tyr	Ala	Leu	Trp	Phe	Cys	Val	Gly	Glu	Ser	Trp
							340		345			350				
Pro	Gln	Asp	Gln	Pro	Trp	Thr	Lys	Arg	Leu	Val	Met	Val	Lys	Val	Va	
							355		360			365				
Pro	Thr	Cys	Leu	Arg	Ala	Leu	Val	Glu	Met	Ala	Arg	Val	Gly	Gly	Ala	
							370	375			380					
Ser	Ser	Leu	Glu	Asn	Thr	Val	Asp	Leu	His	Ile	Asp	Asn	Asp	His	Pr	
							385	390		395					400	
40	Leu	Asp	Leu	Asp	Asp	Asp	Gln	Tyr	Lys	Ala	Tyr	Leu	Gln	Asp	Leu	Va
							405		410			415				
Glu	Gly	Met	Asp	Phe	Gln	Gly	Pro	Gly	Glu	Ser						
							420		425							

<210> 3

<211> 13

<212> PRT

<213> Homo sapiens

50 <400> 3

Ile Ser Asn Ser His Pro Leu Ser Leu Thr Ser Asp Gln  
1 5 10

<210> 4

<211> 4

<212> PRT

<213> Homo sapiens

<400> 4

444

1/30




FIG. 1

2/30




FIG. 2A




FIG. 2B

3/30




FIG. 3A

4/30




FIG. 3B

5/30




FIG. 4A

6/30












FIG. 4B

7/30

FIG. 5A  
wtIRF-3FIG. 5B  
wtIRF-3FIG. 5C  
IRF-3(5A)FIG. 5D  
IRF-3(5A)FIG. 5E  
IRF-3(5D)FIG. 5F  
IRF-3(5D)FIG. 5G  
IRF-3(NES)FIG. 5H  
IRF-3(NES)

8/30

IFN $\beta$ -CAT




FIG. 6A

9/30




FIG. 6B

10/30




FIG. 6C

11/30




FIG. 7A




FIG. 7B

12/30




FIG. 7C




FIG. 7D

13/30




FIG. 8A Endogenous IRF-3




FIG. 8B IRF-3ΔN





FIG. 8C IRF-3ΔN5A

14/30

**FIG. 9A**

15/30




FIG. 9B

CBP-1   CBP-2   CBP-3

Sendai virus - + - + - +




FIG. 9C

CBP-1 → CBP-3

FIG. 9D



17/30

10	20	30	40	
*	*	*	*	
ATG GGA ACC CCA AAG CCA CGG ATC CTG CCC TGG CTG GTG TCG CAG CTG	TAC CCT TGG GGT TTC GGT GCC TAG GAC GGG ACC GAC CAC AGC GTC GAC	M G T P K R I L P W L V S Q L>		
50	60	70	80	90
*	*	*	*	*
GAC CTG GGG CAA CTG GAG GGC GTG GCC TGG GTG AAC AAG AGC CGC ACG	CTG GAC CCC GTT GAC CTC CCG CAC CGG ACC CAC TTG TTC TCG GCG TGC	D L G Q L E G V A W V N K S R T>		
100	110	120	130	140
*	*	*	*	*
CGC TTC CGC ATC CCT TGG AAG CAC GGC CTA CGG CAG GAT GCA CAG CAG	CGC AAG GCG TAG GGA ACC TTC GTG CCG GAT GCC GTC CTA CGT GTC GTC	R F R I P W K H G L R Q D A Q Q>		
150	160	170	180	190
*	*	*	*	*
GAG GAT TTC GGA ATC TTC CAG GCC TGG GCC GAG GCC ACT GGT GCA TAT	CTC CTA AAG CCT TAG AAG GTC CGG ACC CGG CTC CGG TGA CCA CGT ATA	E D F G I F Q A W A E A T G A Y>		
200	210	220	230	240
*	*	*	*	*
GTT CCC GGG AGG GAT AAG CCA GAC CTG CCA ACC TGG AAG AGG AAT TTC	CAA GGG CCC TCC CTA TTC GGT CTG GAC GGT TGG ACC TTC TCC TTA AAG	V P G R D K P D L P T W K R N F>		
250	260	270	280	
*	*	*	*	
CGC TCT GCC CTC AAC CGC AAA GAA GGG TTG CGT TTA GCA GAG GAC CGG	GCG AGA CGG GAG TTG GCG TTT CTT CCC AAC GCA AAT CGT CTC CTG GCC	R S A L N R K E G L R L A E D R>		
290	300	310	320	330
*	*	*	*	*
AGC AAG GAC CCT CAC GAC CCA CAT AAA ATC TAC GAG TTT GTG AAC TCA	TCG TTC CTG GGA GTG CTG GGT GTA TTT TAG ATG CTC AAA CAC TTG AGT	S K D P H D P H K I Y E F V N S>		
340	350	360	370	380
*	*	*	*	*
GGA GTT GGG GAC TTT TCC CAG CCA GAC ACC TCT CCG GAC ACC AAT GGT	CCT CAA CCC CTG AAA AGG GTC CTG TGG AGA GGC CTG TGG TTA CCA	G V G D F S Q P D T S P D T N G>		
390	400	410	420	430
*	*	*	*	*
GGA GGC AGT ACT TCT GAT ACC CAG GAA GAC ATT CTG GAT GAG TTA CTG	CCT CCG TCA TGA AGA CTA TGG GTC CTT CTG TAA GAC CTA CTC AAT GAC	G G S T S D T Q E D I L D E L L>		

FIG. 10

## 18/30

440	450	460	470	480
*	*	*	*	*
GGT AAC ATG GTG TTG GCC CCA CTC CCA GAT CCG GGA CCC CCA AGC CTG				
CCA TTG TAC CAC AAC CGG GGT GAG GGT CTA GGC CCT GGG GGT TCG GAC				
G N M V L A P L P D P G P P S L>				
490                  500                  510                  520				
*	*	*	*	
GCT GTA GCC CCT GAG CCC TGC CCT CAG CCC CTG CGG AGC CCC AGC TTG				
CGA CAT CGG GGA CTC GGG ACG GGA GTC GGG GAC GCC TCG GGG TCG AAC				
A V A P E P C P Q P L R S P S L>				
530                  540                  550                  560                  570				
*	*	*	*	*
GAC AAT CCC ACT CCC TTC CCA AAC CTG GGG CCC TCT GAG AAC CCA CTG				
CTG TTA GGG TGA GGG AAG GGT TTG GAC CCC GGG AGA CTC TTG GGT GAC				
D N P T P F P N L G P S E N P L>				
580                  590                  600                  610                  620				
*	*	*	*	*
AAG CGG CTG TTG GTG CCG GGG GAA GAG TGG GAG TTC GAG GTG ACA GCC				
TTC GCC GAC AAC CAC GCC CCC CTT CTC ACC CTC AAG CTC CAC TGT CGG				
K R L L V P G E E W E F E V T A>				
630                  640                  650                  660                  670				
*	*	*	*	*
TTC TAC CGG GGC CGC CAA GTC TTC CAG CAG ACC ATC TCC TGC CCG GAG				
AAG ATG GCC CCG GCG GTT CAG AAG GTC GTC TGG TAG AGG ACG GGC CTC				
F Y R G R Q V F Q Q T I S C P E>				
680                  690                  700                  710                  720				
*	*	*	*	*
GGC CTG CGG CTG GTG GGG TCC GAA GTG GGA GAC AGG ACG CTG CCT GGA				
CCG GAC GCC GAC CAC CCC AGG CTT CAC CCT CTG TCC TGC GAC GGA CCT				
G L R L V G S E V G D R T L P G>				
730                  740                  750                  760				
*	*	*	*	*
TGG CCA GTC ACA CTG CCA GAC CCT GGC ATG TCC CTG ACA GAC AGG GGA				
ACC GGT CAG TGT GAC GGT CTG GGA CCG TAC AGG GAC TGT CTG TCC CCT				
W P V T L P D P G M S L T D R G>				
770                  780                  790                  800                  810				
*	*	*	*	*
GTG ATG AGC TAC GTG AGG CAT GTG CTG AGC TGC CTG GGT GGG GGA CTG				
CAC TAC TCG ATG CAC TCC GTA CAC GAC TCG ACG GAC CCA CCC CCT GAC				
V M S Y V R H V L S C L G G G L>				
820                  830                  840                  850                  860				
*	*	*	*	*
GCT CTC TGG CGG GCC GGG CAG TGG CTC TGG GCC CAG CGG CTG GGG CAC				
CGA GAG ACC GCC CGG CCC GTC ACC GAG ACC CGG GTC GCC GAC CCC GTG				
A L W R A G Q W L W A Q R L G H>				
870                  880                  890                  900                  910				
*	*	*	*	*
TGC CAC ACA TAC TGG GCA GTG AGC GAG GAG CTG CTC CCC AAC AGC GGG				
ACG GTG TGT ATG ACC CGT CAC TCG CTC CTC GAC GAG GGG TTG TCG CCC				
C H T Y W A V S E E L L P N S G>				


FIG. 10  
CONTINUED

19/30

920            930            940            950            960  
\*            \*            \*            \*            \*  
CAT GGG CCT GAT GGC GAG GTC CCC AAG GAC AAG GAA GGA GGC GTG TTT  
GTA CCC GGA CTA CCG CTC CAG GGG TTC CTG TTC CTT CCT CCG CAC AAA  
H   G   P   D   G   E   V   P   K   D   K   E   G   G   V   F>  
  
970            980            990            1000  
\*            \*            \*            \*  
GAC CTG GGG CCC TTC ATT GTA GAT CTG ATT ACC TTC ACG GAA GGA AGC  
CTG GAC CCC GGG AAG TAA CAT CTA GAC TAA TGG AAG TGC CTT CCT TCG  
D   L   G   P   F   I   V   D   L   I   T   F   T   E   G   S>  
  
1010            1020            1030            1040            1050  
\*            \*            \*            \*            \*  
GGA CGC TCA CCA CGC TAT GCC CTC TGG TTC TGT GTG GGG GAG TCA TGG  
CCT GCG AGT GGT GCG ATA CGG GAG ACC AAG ACA CAC CCC CTC AGT ACC  
G   R   S   P   R   Y   A   L   W   F   C   V   G   E   S   W>  
  
1060            1070            1080            1090            1100  
\*            \*            \*            \*            \*  
CCC CAG GAC CAG CCG TGG ACC AAG AGG CTC GTG ATG GTC AAG GTT GTG  
GGG GTC CTG GTC GGC ACC TGG TTC TCC GAG CAC TAC CAG TTC CAA CAC  
P   Q   D   Q   P   W   T   K   R   L   V   M   V   K   V   V>  
  
1110            1120            1130            1140            1150  
\*            \*            \*            \*            \*  
CCC ACG TGC CTC AGG GCC TTG GTA GAA ATG GCC CGG GTA GGG GGT GCC  
GGG TGC ACG GAG TCC CGG AAC CAT CTT TAC CGG GCC CAT CCC CCA CGG  
P   T   C   L   R   A   L   V   E   M   A   R   V   G   G   A>  
  
1160            1170            1180            1190            1200  
\*            \*            \*            \*            \*  
TCC TCC CTG GAG AAT ACT GTG GAC CTG CAC ATT GAC AAC GAC CAC CCA  
AGG AGG GAC CTC TTA TGA CAC CTG GAC GTG TAA CTG TTG CTG GTG GGT  
S   S   L   E   N   T   V   D   L   H   I   D   N   D   H   P>  
  
1210            1220            1230            1240  
\*            \*            \*            \*  
CTC GAC CTC GAC GAC GAC CAG TAC AAG GCC TAC CTG CAG GAC TTG GTG  
GAG CTG GAG CTG CTG GTC ATG TTC CGG ATG GAC GTC CTG AAC CAC  
L   D   L   D   D   Q   Y   K   A   Y   L   Q   D   L   V>  
  
1250            1260            1270            1280  
\*            \*            \*            \*  
GAG GGC ATG GAT TTC CAG GGC CCT GGG GAG AGC TGA  
CTC CCG TAC CTA AAG GTC CCG GGA CCC CTC TCG ACT  
E   G   M   D   F   Q   G   P   G   E   S>

FIG. 10  
CONTINUED

20/30

**FIG. 11**

09/647965  
PCT/CA99/00314

WO 99/51737

21/30

10            20            30            40  
\*            \*            \*            \*  
ATG GCC TTG GCT CCT GAG AGG GCA GGC CCA CGC GTG CTG TTC GGA GAG  
TAC CGG AAC CGA GGA CTC TCC CGT CGG GGT GCG CAC GAC AAG CCT CTC  
M A L A P E R A A P R V L F G E>  
  
50            60            70            80            90  
\*            \*            \*            \*            \*  
TGG CTC CTT GGA GAG ATC AGC AGC GGC TGC TAT GAG GGG CTG CAG TGG  
ACC GAG GAA CCT CTC TAG TCG TCG CCG ACG ATA CTC CCC GAC GTC ACC  
W L L G E I S S G C Y E G L Q W>  
  
100            110            120            130            140  
\*            \*            \*            \*            \*  
CTG GAC GAG GCC CGC ACC TGT TTC CGC GTG CCC TGG AAG CAC TTC GCG  
GAC CTG CTC CGG GCG TGG ACA AAG GCG CAC GGG ACC TTC GTG AAG CGC  
L D E A R T C F R V P W K H F A>  
  
150            160            170            180            190  
\*            \*            \*            \*            \*  
CGC AAG GAC CTG AGC GAG GCC GAC GCG CGC ATC TTC AAG GCC TGG GCT  
GCG TTC CTG GAC TCG CTC CGG CTG CGC GCG TAG AAG TTC CGG ACC CGA  
R K D L S E A D A R I F K A W A>  
  
200            210            220            230            240  
\*            \*            \*            \*            \*  
GTG GCC CGC GGC AGG TGG CCG CCT AGC AGC AGG GGA GGT GGC CCG CCC  
CAC CGG GCG CGG TCC ACC GGC GGA TCG TCG TCC CCT CCA CGG GGC GGG  
V A R G R W P P S S R G G G P P>  
  
250            260            270            280  
\*            \*            \*            \*  
CCC GAG GCT GAG ACT GCG GAG CGC GCC GGC TGG AAA ACC AAC TTC CGC  
GGG CTC CGA CTC TGA CGC CTC GCG CGG CGG ACC TTT TGG TTG AAG GCG  
P E A E T A E R A G W K T N F R>  
  
290            300            310            320            330  
\*            \*            \*            \*            \*  
TGC GCA CTG CGC AGC ACG CGT CGC TTC GTG ATG CTG CGG GAT AAC TCG  
ACG CGT GAC GCG TCG TGC GCA GCG AAG CAC TAC GAC GCC CTA TTG AGC  
C A L R S T R R F V M L R D N S>  
  
340            350            360            370            380  
\*            \*            \*            \*            \*  
GGG GAC CCG GCC GAC CCG CAC AAG GTG TAC GCG CTC AGC CGG GAG CTG  
CCC CTG GGC CGG CTG GGC GTG TTC CAC ATG CGC GAG TCG GCC CTC GAC  
G D P A D P H K V Y A L S R E L>

FIG. 12

22/30

390	400	410	420	430
*	*	*	*	*
TGC TGG CGA GAA GGC CCA GGC ACG GAC CAG ACT GAG GCA GAG GCC CCC				
ACG ACC GCT CTT CCG GGT CCG TGC CTG GTC TGA CTC CGT CTC CGG GGG				
C W R E G P G T D Q T E A E A P>				
440      450      460      470      480				
*	*	*	*	*
GCA GCT GTC CCA CCA CCA CAG GGT GGG CCC CCA GGG CCA TTC TTG GCA				
CGT CGA CAG GGT GGT GTC CCA CCC GGG GGT CCC GGT AAG AAC CGT				
A A V P P P Q G G P P G P F L A>				
490      500      510      520				
*	*	*	*	
CAC ACA CAT GCT GGA CTC CAA GCC CCA GGC CCC CTC CCT GCC CCA GCT				
GTG TGT GTA CGA CCT GAG GTT CGG GGT CCG GGG GAG GGA CGG GGT CGA				
H T H A G L Q A P G P L P A P A P A>				
530      540      550      560      570				
*	*	*	*	*
GGT GAC AAG GGG GAC CTC CTG CTC CAG GCA GTG CAA CAG AGC TGC CTG				
CCA CTG TTC CCC CTG GAG GAC GAG GTC CGT CAC GTT GTC TCG ACG GAC				
G D K G D L L Q A V Q Q S C L>				
580      590      600      610      620				
*	*	*	*	*
GCA GAC CAT CTG CTG ACA GCG TCA TGG GGG GCA GAT CCA GTC CCA ACC				
CGT CTG GTA GAC GAC TGT CGC AGT ACC CCC CGT CTA GGT CAG GGT TGG				
A D H L L T A S W G A D P V P T>				
630      640      650      660      670				
*	*	*	*	*
AAG GCT CCT GGA GAG GGA CAA GAA GGG CTT CCC CTG ACT GGG GCC TGT				
TTC CGA GGA CCT CTC CCT GTT CTT CCC GAA GGG GAC TGA CCC CGG ACA				
K A P G E G Q E G L P L T G A C>				
680      690      700      710      720				
*	*	*	*	*
GCT GGA GGC CCA GGG CTC CCT GCT GGG GAG CTG TAC GGG TGG GCA GTA				
CGA CCT CCG GGT CCC GAG GGA CGA CCC CTC GAC ATG CCC ACC CGT CAT				
A G G P G L P A G E L Y G W A V>				
730      740      750      760				
*	*	*	*	
GAG ACG ACC CCC AGC CCC GGG CCC CAG CCC GCG GCA CTA ACG ACA GGC				
CTC TGC TGG GGG TCG GGG CCC GGG GTC GGG CGC CGT GAT TGC TGT CCG				
E T T P S P G P Q P A A L T T G>				

FIG. 12  
CONTINUED

09/647965

PCT/CA99/00314

WO 99/51737

23/30

770	780	790	800	810											
*	*	*	*	*											
GAG	GCC	GCG	GCC	CCA	GAG	TCC	CCG	CAC	CAG	GCA	GAG	CCG	TAC	CTG	TCA
CTC	CGG	CGC	CGG	GGT	CTC	AGG	GGC	GTG	GTC	CGT	CTC	GGC	ATG	GAC	AGT
E	A	A	A	P	E	S	P	H	Q	A	E	P	Y	L	S>
820	830	840	850	860	*	*	*	*	*	*	*	*	*	*	*
CCC	TCC	CCA	AGC	GCC	TGC	ACC	GCG	GTG	CAA	GAG	CCC	AGC	CCA	GGG	GCG
GGG	AGG	GGT	TCG	CGG	ACG	TGG	CGC	CAC	GTT	CTC	GGG	TCG	GGT	CCC	CGC
P	S	P	S	A	C	T	A	V	Q	E	P	S	P	G	A>
870	880	890	900	910	*	*	*	*	*	*	*	*	*	*	*
CTG	GAC	GTG	ACC	ATC	ATG	TAC	AAG	GGC	CGC	ACG	GTG	CTG	CAG	AAG	GTG
GAC	CTG	CAC	TGG	TAG	TAC	ATG	TTC	CCG	GCG	TGC	CAC	GAC	GTC	TTC	CAC
L	D	V	T	I	M	Y	K	G	R	T	V	L	Q	K	V>
920	930	940	950	960	*	*	*	*	*	*	*	*	*	*	*
GTG	GGA	CAC	CCG	AGC	TGC	ACG	TTC	CTA	TAC	GGC	CCC	CCA	GAC	CCA	GCT
CAC	CCT	GTG	GGC	TCG	ACG	TGC	AAG	GAT	ATG	CCG	GGG	GGT	CTG	GGT	CGA
V	G	H	P	S	C	T	F	L	Y	G	P	P	D	P	A>
970	980	990	1000		*	*	*	*	*	*	*	*	*	*	*
GTC	CGG	GCC	ACA	GAC	CCC	CAG	CAG	GTA	GCA	TTC	CCC	AGC	CCT	GCC	GAG
CAG	GCC	CGG	TGT	CTG	GGG	GTC	GTC	CAT	CGT	AAG	GGG	TCG	GGA	CGG	CTC
V	R	A	T	D	P	Q	Q	V	A	F	P	S	P	A	E>
1010	1020	1030	1040	1050	*	*	*	*	*	*	*	*	*	*	*
CTC	CCG	GAC	CAG	AAG	CAG	CTG	CGC	TAC	ACG	GAG	GAA	CTG	CTG	CGG	CAC
GAG	GGC	CTG	GTC	TTC	GTC	GAC	GCG	ATG	TGC	CTC	CTT	GAC	GAC	GCC	GTG
L	P	D	Q	K	Q	L	R	Y	T	E	E	L	L	R	H>
1060	1070	1080	1090	1100	*	*	*	*	*	*	*	*	*	*	*
GTG	GCC	CCT	GGG	TTG	CAC	CTG	GAG	CTT	CGG	GGG	CCA	CAG	CTG	TGG	GCC
CAC	CGG	GGA	CCC	AAC	GTG	GAC	CTC	GAA	GCC	CCC	GGT	GTC	GAC	ACC	CGG
V	A	P	G	L	H	L	E	L	R	G	P	Q	L	W	A>
1110	1120	1130	1140	1150	*	*	*	*	*	*	*	*	*	*	*
CGG	CGC	ATG	GGC	AAG	TGC	AAG	GTG	TAC	TGG	GAG	GTG	GGC	GGA	CCC	CCA
GCC	GCG	TAC	CCG	TTC	ACG	TTC	CAC	ATG	ACC	CTC	CAC	CCG	CCT	GGG	GGT
R	R	M	G	K	C	K	V	Y	W	E	V	G	G	P	P>

FIG. 12  
CONTINUED

24/30

1160	1170	1180	1190	1200
*	*	*	*	*
GGC TCC GCC AGC CCC TCC ACC CCA GCC TGC CTG CTG CCT CGG AAC TGT				
CCG AGG CGG TCG GGG AGG TGG GGT CGG ACG GAC GAC GGA GCC TTG ACA				
G S A S P S T P A C L L P R N C>				
1210                  1220                  1230                  1240				
*	*	*	*	*
GAC ACC CCC ATC TTC GAC TTC AGA GTC TTC CAA GAG CTG GTG GAA				
CTG TGG GGG TAG AAG CTG AAG TCT CAG AAG AAG GTT CTC GAC CAC CTT				
D T P I F D F R V F F Q E L V E>				
1250                  1260                  1270                  1280                  1290				
*	*	*	*	*
TTC CGG GCA CGG CAG CGC CGT GGC TCC CCA CGC TAT ACC ATC TAC CTG				
AAG GCC CGT GCC GTC GCG GCA CCG AGG GGT GCG ATA TGG TAG ATG GAC				
F R A R Q R R G S P R Y T I Y L>				
1300                  1310                  1320                  1330                  1340				
*	*	*	*	*
GGC TTC GGG CAG GAC CTG TCA GCT GGG AGG CCC AAG GAG AAG AGC CTG				
CCG AAG CCC GTC CTG GAC AGT CGA CCC TCC GGG TTC CTC TTC TCG GAC				
G F G Q D L S A G R P K E K S L>				
1350                  1360                  1370                  1380                  1390				
*	*	*	*	*
GTC CTG GTG AAG CTG GAA CCC TGG CTG TGC CGA GTG CAC CTA GAG GGC				
CAG GAC CAC TTC GAC CTT GGG ACC GAC ACG GCT CAC GTG GAT CTC CCG				
V L V K L E P W L C R V H L E G>				
1400                  1410                  1420                  1430                  1440				
*	*	*	*	*
ACG CAG CGT GAG GGT GTG TCT TCC CTG GAT AGC AGC GAC CTC GAC CTC				
TGC GTC GCA CTC CCA CAC AGA AGG GAC CTA TCG TCG CTG GAG CTG GAG				
T Q R E G V S S L D S S D L D L>				
1450                  1460                  1470                  1480				
*	*	*	*	
TGC CTG TCC AGC GCC AAC AGC CTC TAT GAC GAC ATC GAG TGC TTC CTT				
ACG GAC AGG TCG CGG TTG TCG GAG ATA CTG CTG TAG CTC ACG AAG GAA				
C L S S A N S L Y D D I E C F L>				
1490                  1500                  1510				
*	*	*		
ATG GAG CTG GAG CAG CCC GCC TAG				
TAC CTC GAC CTC GTC GGG CGG ATC				
M E L E Q P A>				

FIG. 12  
CONTINUED

09/647965

PCT/CA99/00314

WO 99/51737

## 25/30

10	20	30	40	
*	*	*	*	
ATG GCC TTG GCT CCT GAG AGG GCA GCC CCA CGC GTG CTG TTC GGA GAG	TAC CGG AAC CGA GGA CTC TCC CGT CGG GGT GCG CAC GAC AAG CCT CTC	M A L A P E R A A P R V L F G E>		
50	60	70	80	90
*	*	*	*	*
TGG CTC CTT GGA GAG ATC AGC AGC GGC TGC TAT GAG GGG CTG CAG TGG	ACC GAG GAA CCT CTC TAG TCG TCG CCG ACG ATA CTC CCC GAC GTC ACC	W L L G E I S S G C Y E G L Q W>		
100	110	120	130	140
*	*	*	*	*
CTG GAC GAG GCC CGC ACC TGT TTC CGC GTG CCC TGG AAG CAC TTC GCG	GAC CTG CTC CGG GCG TGG ACA AAG GCG CAC GGG ACC TTC GTG AAG CGC	L D E A R T C F R V P W K H F A>		
150	160	170	180	190
*	*	*	*	*
CGC AAG GAC CTG AGC GAG GCC GAC GCG CGC ATC TTC AAG GCC TGG GCT	GCG TTC CTG GAC TCG CTC CGG CTG CGC GCG TAG AAG TTC CGG ACC CGA	R K D L S E A D A R I F K A W A>		
200	210	220	230	240
*	*	*	*	*
GTG GCC CGC GGC AGG TGG CCG CCT AGC AGC AGG GGA GGT GGC CCG CCC	CAC CGG GCG CCG TCC ACC GGC GGA TCG TCG TCC CCT CCA CCG GGC GGG	V A R G R W P P S S R G G G P P>		
250	260	270	280	
*	*	*	*	
CCC GAG GCT GAG ACT GCG GAG CGC GCC GGC TGG AAA ACC AAC TTC CGC	GGG CTC CGA CTC TGA CGC CTC CGC CGG CCG ACC TTT TGG TTG AAG GCG	P E A E T A E R A G W K T N F R>		
290	300	310	320	330
*	*	*	*	*
TGC GCA CTG CGC AGC ACG CGT CGC TTC GTG ATG CTG CGG GAT AAC TCG	ACG CGT GAC GCG TCG TGC GCA GCG AAG CAC TAC GAC GCC CTA TTG AGC	C A L R S T R R F V M L R D N S>		

FIG. 13

26/30

340	350	360	370	380
*	*	*	*	*
GGG GAC CCG GCC GAC CCG CAC AAG GTG TAC GCG CTC AGC CGG GAG CTG				
CCC CTG GGC CGG CTG GGC GTG TTC CAC ATG CGC GAG TCG GCC CTC GAC				
G D P A D P H K V Y A L S R E L>				
390	400	410	420	430
*	*	*	*	*
TGC TGG CGA GAA GGC CCA GGC ACG GAC CAG ACT GAG GCA GAG GCC CCC				
ACG ACC GCT CTT CCG GGT CCG TGC CTG GTC TGA CTC CGT CTC CGG GGG				
C W R E G P G T D Q T E A E A P>				
440	450	460	470	480
*	*	*	*	*
GCA GCT GTC CCA CCA CCA CAG GGT GGG CCC CCA GGG CCA TTC TTG GCA				
CGT CGA CAG GGT GGT GTC CCA CCC GGG GGT CCC GGT AAG AAC CGT				
A A V P P Q G G P P G P F L A>				
490	500	510	520	
*	*	*	*	
CAC ACA CAT GCT GGA CTC CAA GCC CCA GGC CCC CTC CCT GCC CCA GCT				
GTG TGT GTA CGA CCT GAG GTT CGG GGT CCG GGG GAG GGA CGG GGT CGA				
H T H A G L Q A P G P L P A P A>				
530	540	550	560	570
*	*	*	*	*
GGT GAC AAG GGG GAC CTC CTG CTC CAG GCA GTG CAA CAG AGC TGC CTG				
CCA CTG TTC CCC CTG GAG GAC GAG GTC CGT CAC GTT GTC TCG ACG GAC				
G D K G D L L Q A V Q Q S C L>				
580	590	600	610	620
*	*	*	*	*
GCA GAC CAT CTG CTG ACA GCG TCA TGG GGG GCA GAT CCA GTC CCA ACC				
CGT CTG GTA GAC GAC TGT CGC AGT ACC CCC CGT CTA GGT CAG GGT TGG				
A D H L L T A S W G A D P V P T>				
630	640	650	660	670
*	*	*	*	*
AAG GCT CCT GGA GAG GGA CAA GAA GGG CTT CCC CTG ACT GGG GCC TGT				
TTC CGA GGA CCT CTC CCT GTT CTT CCC GAA GGG GAC TGA CCC CGG ACA				
K A P G E G Q E G L P L T G A C>				
680	690	700	710	720
*	*	*	*	*
GCT GGA GGC CCA GGG CTC CCT GCT GGG GAG CTG TAC GGG TGG GCA GTA				
CGA CCT CCG GGT CCC GAG GGA CGA CCC CTC GAC ATG CCC ACC CGT CAT				
A G G P G L P A G E L Y G W A V>				

FIG. 13  
CONTINUED

27/30

730	740	750	760	
*	*	*	*	
GAG ACG ACC CCC AGC CCC ACT TCT GAT ACC CAG GAA GAC ATT CTG GAT	CTC TGC TGG GGG TCG GGG TGA AGA CTA TGG GTC CTT CTG TAA GAC CTA			
E T T P S P T S D T Q E D I L D>				
* * * * *				
770	780	790	800	810
*	*	*	*	*
GAG TTA CTG GGT AAC ATG GTG TTG GCC CCA CTC CCA GAT CCG GGA CCC	CTC AAT GAC CCA TTG TAC CAC AAC CGG GGT GAG GGT CTA GGC CCT GGG			
E L L G N M V L A P L P D P G P>				
* * * * *				
820	830	840	850	860
*	*	*	*	*
CCA AGC CTG GCT GTA GCC CCT GAG CCC TGC CCT CAG CCC CTG CGG AGC	GGT TCG GAC CGA CAT CGG GGA CTC GGG ACG GGA GTC GGG GAC GCC TCG			
P S L A V A P E P C P Q P L R S>				
* * * * *				
870	880	890	900	910
*	*	*	*	*
CCC AGC TTG GAC AAT CCC ACT CCC TTC CCA AAC CTG GGG CCC TCT GAG	GGG TCG AAC CTG TTA GGG TGA GGG AAG GGT TTG GAC CCC GGG AGA CTC			
P S L D N P T P F P N L G P S E>				
* * * * *				
920	930	940	950	960
*	*	*	*	*
AAC CCA CTG AAG CGG CTG TTG GTG CCG GGG GAA GAG TGG GAG TTC GAG	TTG GGT GAC TTC GCC GAC AAC CAC GGC CCC CTT CTC ACC CTC AAG CTC			
N P L K R L L V P G E E W E F E>				
* * * * *				
970	980	990	1000	
*	*	*	*	
G TG ACA GCC TTC TAC CGG GGC CGC CAA GTC TTC CAG CAG ACC ATC TCC	CAC TGT CGG AAG ATG GCC CCG GCG GTT CAG AAG GTC GTC TGG TAG AGG			
V T A F Y R G R Q V F Q Q T I S>				
* * * * *				
1010	1020	1030	1040	1050
*	*	*	*	*
TGC CCG GAG GGC CTG CGG CTG GTG GGG TCC GAA GTG GGA GAC AGG ACG	ACG GGC CTC CCG GAC GCC GAC CAC CCC AGG CTT CAC CCT CTG TCC TGC			
C P E G L R L V G S E V G D R T>				
* * * * *				
1060	1070	1080	1090	1100
*	*	*	*	*
CTG CCT GGA TGG CCA GTC ACA CTG CCA GAC CCT GGC ATG TCC CTG ACA	GAC GGA CCT ACC GGT CAG TGT GAC GGT CTG GGA CCG TAC AGG GAC TGT			
L P G W P V T L P D P G M S L T>				

**FIG. 13**  
**CONTINUED**

28/30

1110	1120	1130	1140	1150											
*	*	*	*	*											
GAC	AGG	GGA	GTG	ATG	AGC	TAC	GTG	AGG	CAT	GTG	CTG	AGC	TGC	CTG	GGT
CTG	TCC	CCT	CAC	TAC	TCG	ATG	CAC	TCC	GTA	CAC	GAC	TCG	ACG	GAC	CCA
D	R	G	V	M	S	Y	V	R	H	V	L	S	C	L	G>
1160	1170	1180	1190	1200	*	*	*	*	*	*	*	*	*	*	*
GGG	GGA	CTG	CCT	TCG	CGG	GCC	GGG	CAG	TGG	CTC	TGG	GCC	CAG	CGG	
CCC	CCT	GAC	CGA	GAG	ACC	GCC	CGG	CCC	GTC	ACC	GAG	ACC	CGG	GTC	GCC
G	G	L	A	L	W	R	A	G	Q	W	L	W	A	Q	R>
1210	1220	1230	1240	*	*	*	*	*	*	*	*	*	*	*	*
CTG	GGG	CAC	TGC	CAC	ACA	TAC	TGG	GCA	GTG	AGC	GAG	GAG	CTG	CTC	CCC
GAC	CCC	GTG	ACG	GTG	TGT	ATG	ACC	CGT	CAC	TCG	CTC	CTC	GAC	GAG	GGG
L	G	H	C	H	T	Y	W	A	V	S	E	E	L	L	P>
1250	1260	1270	1280	1290	*	*	*	*	*	*	*	*	*	*	*
AAC	AGC	GGG	CAT	GGG	CCT	GAT	GGC	GAG	GTC	CCC	AAG	GAC	AAG	GAA	GGA
TTG	TCG	CCC	GTA	CCC	GGA	CTA	CCG	CTC	CAG	GGG	TTC	CTG	TTC	CTT	CCT
N	S	G	H	G	P	D	G	E	V	P	K	D	K	E	G>
1300	1310	1320	1330	1340	*	*	*	*	*	*	*	*	*	*	*
GGC	GTG	TTT	GAC	CTG	GGG	CCC	TTC	ATT	GTA	GAT	CTG	ATT	ACC	TTC	ACG
CCG	CAC	AAA	CTG	GAC	CCC	GGG	AAG	TAA	CAT	CTA	GAC	TAA	TGG	AAG	TGC
G	V	F	D	L	G	P	F	I	V	D	L	I	T	F	T>
1350	1360	1370	1380	1390	*	*	*	*	*	*	*	*	*	*	*
GAA	GGA	AGC	GGA	CGC	TCA	CCA	CGC	TAT	GCC	CTC	TGG	TTC	TGT	GTG	GGG
CTT	CCT	TCG	CCT	CGC	AGT	GGT	GCG	ATA	CGG	GAG	ACC	AAG	ACA	CAC	CCC
E	G	S	G	R	S	P	R	Y	A	L	W	F	C	V	G>
1400	1410	1420	1430	1440	*	*	*	*	*	*	*	*	*	*	*
GAG	TCA	TGG	CCC	CAG	GAC	CAG	CCG	TGG	ACC	AAG	AGG	CTC	GTG	ATG	GTC
CTC	AGT	ACC	GGG	GTC	CTG	GTC	GGC	ACC	TGG	TTC	TCC	GAG	CAC	TAC	CAG
E	S	W	P	Q	D	Q	P	W	T	K	R	L	V	M	V>
1450	1460	1470	1480	*	*	*	*	*	*	*	*	*	*	*	*
AAG	GTT	GTG	CCC	ACG	TGC	CTC	AGG	GCC	TTG	GTA	GAA	ATG	GCC	CGG	GTA
TTC	CAA	CAC	GGG	TGC	ACG	GAG	TCC	CGG	AAC	CAT	CTT	TAC	CGG	GCC	CAT
K	V	V	P	T	C	L	R	A	L	V	E	M	A	R	V>
1490	1500	1510	1520	1530	*	*	*	*	*	*	*	*	*	*	*
GGG	GGT	GCC	TCC	TCC	CTG	GAG	AAT	ACT	GTG	GAC	CTG	CAC	ATT	GAC	AAC
CCC	CCA	CGG	AGG	AGG	GAC	CTC	TTA	TGA	CAC	CTG	GAC	GTG	TAA	CTG	TTG
G	G	A	S	S	L	E	N	T	V	D	L	H	I	D	N>

FIG. 13  
CONTINUED

29/30

1540	1550	1560	1570	1580
*	*	*	*	*
GAC CAC CCA CTC GAC CTC GAC GAC GAC CAG TAC AAG GCC TAC CTG CAG				
CTG GTG GGT GAG CTG GAG CTG CTG CTG GTC ATG TTC CGG ATG GAC GTC				
D H P L D L D D Q Y K A Y L Q>				
1590	1600	1610	1620	
*	*	*	*	
GAC TTG GTG GAG GGC ATG GAT TTC CAG GGC CCT GGG GAG AGC TGA				
CTG AAC CAC CTC CCG TAC CTA AAG GTC CCG GGA CCC CTC TCG ACT				
D L V E G M D F Q G P G E S>				

FIG. 13  
CONTINUED

30/30




FIG. 14

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINS**

the specification of which

(check one)  is attached hereto.

was filed on October 6, 2000

as U.S. Application Serial No. 09/647,965

was filed on \_\_\_\_\_

as PCT International Application No. \_\_\_\_\_

and (if applicable) was amended on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §§1.56(a) and (b), which state:

- "(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
  - (1) prior art cited in search reports of a foreign patent office in a counterpart application,
  - (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
- (2) It refutes, or is inconsistent with, a position the applicant takes in:
  - (i) Opposing an argument of unpatentability relied on by the Office, or
  - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability."

I hereby claim foreign priority benefits under 35 United States Code, §119 and/or §365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing of this application:

PRIOR FOREIGN APPLICATION(S)

<u>Number</u>	<u>Country</u>	<u>Filing Date (Month/Day/Year)</u>	<u>Date First Laid-open or Published</u>	<u>Date Patented or Granted</u>	<u>Priority Claimed?</u>
2234588	CA	04/07/98			

I hereby claim the benefit under 35 United States Code, §119(e) of any United States provisional application(s) listed below:

<u>Application Number</u>	<u>Filing Date</u>
---------------------------	--------------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

PRIOR U.S. OR PCT APPLICATION(S)

<u>Application No.</u>	<u>Filing Date (month/day/year)</u>	<u>Status (pending, abandoned, granted)</u>
PCT/CA99/00314	04/07/99	PENDING

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following patent agents with full power of substitution, association and revocation to prosecute this application and/or international application and to transact all business in the Patent and Trademark Office connected therewith:

JAMES D. KOKONIS (Reg. No. 21178)  
ALAN R. CAMPBELL (Reg. No. 26129)  
A. DAVID MORROW (Reg. No. 28816)  
JAMES MCGRAW (Reg. No. 28168)  
JOHN BOCHNOVIC (Reg. No. 29229)  
JOY D. MORROW (Reg. No. 30911)  
TOKUO HIRAMA (Reg. No. 32551)  
PHILIP D. LAPIN (Reg. No. 44443)  
CHRISTINE N. GENGE (Reg. No. 45405)  
DENNIS S. K. LEUNG (Reg. No. 47325)  
DANA M. RAYMOND (Reg. No. 18540)  
FRANCIS J. HONE (Reg. No. 18662)  
ARTHUR S. TENSER (Reg. No. 18839)  
THOMAS R. NESBITT, JR. (Reg. No. 22075)  
RICHARD G. BERKLEY (Reg. No. 25465)  
BRADLEY B. GEIST (Reg. No. 27551)  
JOHN D. MURNANE (Reg. No. 29836)  
ROBERT C. SCHEINFELD (Reg. No. 31300)  
LOUIS S. SORELL (Reg. No. 32439)  
GARY M. BUTTER (Reg. No. 33841)  
LISA B. KOLE (Reg. No. 35225)

HUGH O'GORMAN (Reg. No. 26140)  
R. ALLAN BRETT (Reg. No. 40476)  
ROBERT D. GOULD (Reg. No. 27523)  
THOMAS R. KELLY (Reg. No. 29244)  
MICHAEL E. WHEELER (Reg. No. 29246)  
DONALD F. PHENIX (Reg. No. 32528)  
KOHJI SUZUKI (Reg. No. 44467)  
R. JOHN HALEY (Reg. No. 29,502)  
HANS KOENIG (Reg. No. 46474)  
THUY HUONG NGUYEN (Reg. No. 47336)  
FREDERICK C. CARVER (Reg. No. 17021)  
JOSEPH D. GARON (Reg. No. 20420)  
RONALD B. HILDRETH (Reg. No. 19,498)  
ROBERT NEUNER (Reg. No. 24316)  
RICHARD S. CLARK (Reg. No. 26154)  
JAMES J. MAUNE (Reg. No. 26946)  
HENRY TANG (Reg. No. 29705)  
JOHN A. FOGARTY, JR. (Reg. No. 22348)  
ROCHELLE K. SEIDE (Reg. No. 32300)  
MARTA E. DELSIGNORE (Reg. No. 32689)

PLEASE SEND CORRESPONDENCE TO:

**Customer No. 21003**  
BAKER BOTTS L.L.P.  
30 Rockefeller Plaza  
New York, New York  
10112 U.S.A.  
Tel: (212) 705-5000

1) INVENTOR'S SIGNATURE: J. H. H. Date: JANUARY 8, 2001

Inventor's Name: John Hiscott  
(First) (Middle) (Family Name)

Country of Citizenship: CANADA

Residence: Montreal, Quebec, Canada PQC  
(City, Province, Country)

Post Office Address: 132 Sheraton Drive, Montreal West, Quebec, Canada H4X 1N4

2) INVENTOR'S SIGNATURE: Jin Rongtuan Date: Jan. 8, 2001

Inventor's Name: Rongtuan Lin  
(First) (Middle) (Family Name)

Country of Citizenship: CANADA

Residence: Montreal, Quebec, Canada PQC  
(City, Province, Country)

Post Office Address: Apartment 17, 4455 Dupuis, Montreal, Quebec, Canada H3T 1E7

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) AND 1.27 (b)) - INDEPENDENT INVENTOR**

Docket No.  
76023-36

Serial No. <b>09/647,965</b>	Filing Date <b>10.06.00</b>	Patent No.	Issue Date
---------------------------------	--------------------------------	------------	------------

Applicant/  
Patentee: **HISCOTT, John and LIN, Rongtuan**

Invention:

**HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINS**

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled above and described in:

- the specification to be filed herewith.
- the application identified above.
- the patent identified above.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- No such person, concern or organization exists.
- Each such person, concern or organization is listed below.

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27)

FULL NAME **SIR MORTIMER B. DAVIS - JEWISH GENERAL HOSPITAL**

ADDRESS **3755 Chemin de la Côte-Ste-Catherine, Montreal, Quebec, H3T 1E2**

Individual       Small Business Concern       Nonprofit Organization

FULL NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

Individual       Small Business Concern       Nonprofit Organization

FULL NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

Individual       Small Business Concern       Nonprofit Organization

FULL NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

Individual       Small Business Concern       Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF INVENTOR John HISCOTT

SIGNATURE OF INVENTOR 

DATE: January 8, 2001

NAME OF INVENTOR Rongtuan LIN

SIGNATURE OF INVENTOR 

DATE: Jan. 8, 2001

NAME OF INVENTOR \_\_\_\_\_

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE: \_\_\_\_\_

NAME OF INVENTOR \_\_\_\_\_

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE: \_\_\_\_\_

NAME OF INVENTOR \_\_\_\_\_

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE: \_\_\_\_\_

NAME OF INVENTOR \_\_\_\_\_

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE: \_\_\_\_\_

NAME OF INVENTOR \_\_\_\_\_

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE: \_\_\_\_\_

NAME OF INVENTOR \_\_\_\_\_

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE: \_\_\_\_\_

NAME OF INVENTOR \_\_\_\_\_

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE: \_\_\_\_\_

NAME OF INVENTOR \_\_\_\_\_

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE: \_\_\_\_\_

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION**

Docket No.  
76023-36

Serial No.	Filing Date	Patent No.	Issue Date
09/647,965	10/06/00		

Applicant/  
Patentee: **HISCOTT, John and LIN, Rongtuan**

Invention:

**HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINS**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: **SIR MORTIMER B. DAVIS - JEWISH GENERAL HOSPITAL**

ADDRESS OF ORGANIZATION: **3755 Chemin de la Cote-Ste-Catherine**

**Montreal, Quebec**

**H3T 1E2 Canada**

**TYPE OF NONPROFIT ORGANIZATION:**

- University or other Institute of Higher Education
- Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))
- Nonprofit Scientific or Educational under Statute of State of The United States of America
 

Name of State:	Citation of Statute:
----------------	----------------------
- Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America
- Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America
 

Name of State:	Citation of Statute:
----------------	----------------------

I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- the specification to be filed herewith.
- the application identified above.
- the patent identified above.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- no such person, concern or organization exists.
- each such person, concern or organization is listed below.

FULL NAME	<hr/>		
ADDRESS	<input type="checkbox"/> Individual	<input type="checkbox"/> Small Business Concern	<input type="checkbox"/> Nonprofit Organization
FULL NAME	<hr/>		
ADDRESS	<input type="checkbox"/> Individual	<input type="checkbox"/> Small Business Concern	<input type="checkbox"/> Nonprofit Organization
FULL NAME	<hr/>		
ADDRESS	<input type="checkbox"/> Individual	<input type="checkbox"/> Small Business Concern	<input type="checkbox"/> Nonprofit Organization
FULL NAME	<hr/>		
ADDRESS	<input type="checkbox"/> Individual	<input type="checkbox"/> Small Business Concern	<input type="checkbox"/> Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: SAMUEL O. FREEDMAN, M.D.


TITLE IN ORGANIZATION: SPECIAL ADVISOR

ADDRESS OF PERSON SIGNING: ROOM B-115  
LADY DAVIS INSTITUTE FOR MEDICAL RESEARCH  
THE SIR MORTIMER B. DAVIS - JEWISH GENERAL HOSPITAL  
3755 CHEMIN DE LA CÔTE-STE-CATHERINE  
MONTREAL, QUEBEC H3T 1E2

SIGNATURE: Samuel O. Freedman

DATE: Jan 8, 2001

United States Patent & Trademark Office  
Office of Initial Patent Examination – Scanning Division



Application deficiencies found during scanning:

Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

*Scanned copy is best available.* Drawing figures  
1, 4B, 5A - 5H, 7B, 7C, 8A - C, 9B - D,  
are dark.